WO2001098294A2 - Vitronectin receptor antagonist pharmaceuticals for use in combination therapy - Google Patents
Vitronectin receptor antagonist pharmaceuticals for use in combination therapy Download PDFInfo
- Publication number
- WO2001098294A2 WO2001098294A2 PCT/US2001/019794 US0119794W WO0198294A2 WO 2001098294 A2 WO2001098294 A2 WO 2001098294A2 US 0119794 W US0119794 W US 0119794W WO 0198294 A2 WO0198294 A2 WO 0198294A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- aryl
- group
- independently selected
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 35
- 238000002648 combination therapy Methods 0.000 title abstract description 13
- 102100022337 Integrin alpha-V Human genes 0.000 title description 13
- 108010048673 Vitronectin Receptors Proteins 0.000 title description 13
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 99
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 49
- 230000008685 targeting Effects 0.000 claims abstract description 41
- 125000005647 linker group Chemical group 0.000 claims abstract description 38
- 230000033115 angiogenesis Effects 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 125000003118 aryl group Chemical group 0.000 claims description 392
- 125000000217 alkyl group Chemical group 0.000 claims description 383
- -1 carbonyl- Chemical group 0.000 claims description 265
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 134
- 125000000623 heterocyclic group Chemical group 0.000 claims description 133
- 125000001072 heteroaryl group Chemical group 0.000 claims description 120
- 229910052757 nitrogen Inorganic materials 0.000 claims description 114
- 229910052717 sulfur Inorganic materials 0.000 claims description 110
- 239000003446 ligand Substances 0.000 claims description 105
- 125000005842 heteroatom Chemical group 0.000 claims description 103
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 100
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 82
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 81
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 79
- 239000012217 radiopharmaceutical Substances 0.000 claims description 79
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 73
- 125000003545 alkoxy group Chemical group 0.000 claims description 71
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 125000004429 atom Chemical group 0.000 claims description 65
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 61
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 claims description 59
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 55
- 125000003342 alkenyl group Chemical group 0.000 claims description 55
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 55
- 229910006069 SO3H Inorganic materials 0.000 claims description 53
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 239000002738 chelating agent Substances 0.000 claims description 48
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 47
- 150000003839 salts Chemical class 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 239000002246 antineoplastic agent Substances 0.000 claims description 40
- 239000003504 photosensitizing agent Substances 0.000 claims description 40
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 37
- 238000003384 imaging method Methods 0.000 claims description 37
- 239000007983 Tris buffer Substances 0.000 claims description 33
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 33
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 210000001519 tissue Anatomy 0.000 claims description 31
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000001475 halogen functional group Chemical group 0.000 claims description 28
- 229910052751 metal Inorganic materials 0.000 claims description 28
- 239000002184 metal Substances 0.000 claims description 28
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 27
- 239000007997 Tricine buffer Substances 0.000 claims description 27
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 27
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 27
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 26
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 26
- 235000019260 propionic acid Nutrition 0.000 claims description 26
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 25
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 24
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 24
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 21
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 20
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 20
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 19
- HCUYBKSYBNTIAK-UHFFFAOYSA-N 2-(6-aminohexanoylamino)-3-[[1-[3-(1h-imidazol-2-ylamino)propyl]indazole-5-carbonyl]amino]propanoic acid Chemical compound N1=CC2=CC(C(=O)NCC(NC(=O)CCCCCN)C(O)=O)=CC=C2N1CCCNC1=NC=CN1 HCUYBKSYBNTIAK-UHFFFAOYSA-N 0.000 claims description 19
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 18
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 18
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 18
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 18
- 229910018830 PO3H Inorganic materials 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 239000003638 chemical reducing agent Substances 0.000 claims description 17
- 229910052740 iodine Inorganic materials 0.000 claims description 17
- 229920000858 Cyclodextrin Chemical group 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 229910052801 chlorine Inorganic materials 0.000 claims description 16
- 229910052731 fluorine Inorganic materials 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 14
- 239000000651 prodrug Chemical group 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical group NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 238000002428 photodynamic therapy Methods 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- DYCLHZPOADTVKK-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-4-yl)acetate Chemical compound NC1=NC(CC(O)=O)=CS1 DYCLHZPOADTVKK-UHFFFAOYSA-N 0.000 claims description 12
- 229930182831 D-valine Chemical group 0.000 claims description 12
- 229910004727 OSO3H Inorganic materials 0.000 claims description 12
- 150000005347 biaryls Chemical group 0.000 claims description 12
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 102000006992 Interferon-alpha Human genes 0.000 claims description 11
- 108010047761 Interferon-alpha Proteins 0.000 claims description 11
- 102000003996 Interferon-beta Human genes 0.000 claims description 11
- 108090000467 Interferon-beta Proteins 0.000 claims description 11
- 230000002159 abnormal effect Effects 0.000 claims description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 11
- 229960001388 interferon-beta Drugs 0.000 claims description 11
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 11
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 150000001723 carbon free-radicals Chemical group 0.000 claims description 10
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 10
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 9
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 9
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 9
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 9
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims description 9
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 9
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 claims description 9
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 9
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 9
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 9
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 claims description 9
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 claims description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 102000008070 Interferon-gamma Human genes 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 9
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims description 9
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 9
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 claims description 9
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims description 9
- 229930192392 Mitomycin Natural products 0.000 claims description 9
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 9
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims description 9
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 9
- OCOKWVBYZHBHLU-UHFFFAOYSA-N Sobuzoxane Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 claims description 9
- 108010078233 Thymalfasin Proteins 0.000 claims description 9
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims description 9
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 9
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 9
- 229960003437 aminoglutethimide Drugs 0.000 claims description 9
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 9
- 229960001220 amsacrine Drugs 0.000 claims description 9
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 9
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 9
- 229960000997 bicalutamide Drugs 0.000 claims description 9
- 229960004562 carboplatin Drugs 0.000 claims description 9
- 229960002115 carboquone Drugs 0.000 claims description 9
- 229960003261 carmofur Drugs 0.000 claims description 9
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 9
- 229960003230 cetrorelix Drugs 0.000 claims description 9
- 108700008462 cetrorelix Proteins 0.000 claims description 9
- 229960002436 cladribine Drugs 0.000 claims description 9
- 229960000684 cytarabine Drugs 0.000 claims description 9
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 9
- 229960000975 daunorubicin Drugs 0.000 claims description 9
- 229960002923 denileukin diftitox Drugs 0.000 claims description 9
- 108010017271 denileukin diftitox Proteins 0.000 claims description 9
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 9
- 229950005454 doxifluridine Drugs 0.000 claims description 9
- 229960004679 doxorubicin Drugs 0.000 claims description 9
- 229950000549 elliptinium acetate Drugs 0.000 claims description 9
- 229950011487 enocitabine Drugs 0.000 claims description 9
- 229950002973 epitiostanol Drugs 0.000 claims description 9
- GOZRRIWDZQPGMN-UHFFFAOYSA-N ethyl 2-[5-(7h-purin-6-ylsulfanyl)pentanoylamino]acetate Chemical compound CCOC(=O)CNC(=O)CCCCSC1=NC=NC2=C1NC=N2 GOZRRIWDZQPGMN-UHFFFAOYSA-N 0.000 claims description 9
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 9
- 229960005420 etoposide Drugs 0.000 claims description 9
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims description 9
- 229960002199 etretinate Drugs 0.000 claims description 9
- 229950011548 fadrozole Drugs 0.000 claims description 9
- 229960002074 flutamide Drugs 0.000 claims description 9
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 9
- 229960004421 formestane Drugs 0.000 claims description 9
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims description 9
- 229960004783 fotemustine Drugs 0.000 claims description 9
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 9
- 229960005277 gemcitabine Drugs 0.000 claims description 9
- 150000002431 hydrogen Chemical class 0.000 claims description 9
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 9
- 229960001101 ifosfamide Drugs 0.000 claims description 9
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 claims description 9
- 229950008097 improsulfan Drugs 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229960003130 interferon gamma Drugs 0.000 claims description 9
- 229960005280 isotretinoin Drugs 0.000 claims description 9
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 claims description 9
- 229960005417 ketanserin Drugs 0.000 claims description 9
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 9
- 229960003881 letrozole Drugs 0.000 claims description 9
- 229960001614 levamisole Drugs 0.000 claims description 9
- 229960003587 lisuride Drugs 0.000 claims description 9
- 229950009246 mepitiostane Drugs 0.000 claims description 9
- 229960000485 methotrexate Drugs 0.000 claims description 9
- 229960005485 mitobronitol Drugs 0.000 claims description 9
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 claims description 9
- 229950010913 mitolactol Drugs 0.000 claims description 9
- 229960004857 mitomycin Drugs 0.000 claims description 9
- 229950007221 nedaplatin Drugs 0.000 claims description 9
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 claims description 9
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 9
- 229960001420 nimustine Drugs 0.000 claims description 9
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 claims description 9
- 229950008607 nitracrine Drugs 0.000 claims description 9
- 229960005244 oxymetholone Drugs 0.000 claims description 9
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 claims description 9
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 claims description 9
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 9
- 229960002340 pentostatin Drugs 0.000 claims description 9
- 229960004694 prednimustine Drugs 0.000 claims description 9
- 229960003387 progesterone Drugs 0.000 claims description 9
- 239000000186 progesterone Substances 0.000 claims description 9
- 229960003857 proglumide Drugs 0.000 claims description 9
- 229960004432 raltitrexed Drugs 0.000 claims description 9
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 claims description 9
- 229960000460 razoxane Drugs 0.000 claims description 9
- 239000003488 releasing hormone Substances 0.000 claims description 9
- 229950010372 sobuzoxane Drugs 0.000 claims description 9
- 229960001052 streptozocin Drugs 0.000 claims description 9
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 9
- 229960001603 tamoxifen Drugs 0.000 claims description 9
- 229960001674 tegafur Drugs 0.000 claims description 9
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 9
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 9
- 229960001278 teniposide Drugs 0.000 claims description 9
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 9
- 229960004231 thymalfasin Drugs 0.000 claims description 9
- 229960001727 tretinoin Drugs 0.000 claims description 9
- 229950005577 vesnarinone Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 9
- 229960004528 vincristine Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 9
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 9
- 229960004355 vindesine Drugs 0.000 claims description 9
- FKBHRUQOROFRGD-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2[C]3C=CC=CC3=NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC FKBHRUQOROFRGD-IELIFDKJSA-N 0.000 claims description 9
- 229960002066 vinorelbine Drugs 0.000 claims description 9
- 229950009268 zinostatin Drugs 0.000 claims description 9
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 8
- 150000001720 carbohydrates Chemical group 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 229920001515 polyalkylene glycol Chemical group 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 230000004044 response Effects 0.000 claims description 8
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-Valine Natural products CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- 239000004472 Lysine Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 150000004035 chlorins Chemical class 0.000 claims description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 7
- UUJSXEHRMRPYEX-UHFFFAOYSA-N n'-(3-nitroquinolin-4-yl)morpholine-4-carboximidamide Chemical compound [O-][N+](=O)C=1C=NC2=CC=CC=C2C=1N=C(N)N1CCOCC1 UUJSXEHRMRPYEX-UHFFFAOYSA-N 0.000 claims description 7
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 claims description 7
- 229940109328 photofrin Drugs 0.000 claims description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
- 229960004295 valine Drugs 0.000 claims description 7
- OFYAYGJCPXRNBL-GFCCVEGCSA-N (2r)-2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(C[C@@H]([NH3+])C([O-])=O)=CC=CC2=C1 OFYAYGJCPXRNBL-GFCCVEGCSA-N 0.000 claims description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical group OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 6
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 6
- 229930182832 D-phenylalanine Natural products 0.000 claims description 6
- 229930195709 D-tyrosine Natural products 0.000 claims description 6
- 125000002849 D-tyrosine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 6
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical group CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 6
- 125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 claims description 6
- 235000019766 L-Lysine Nutrition 0.000 claims description 6
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims description 6
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical group CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 6
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 6
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000001671 coumarin Nutrition 0.000 claims description 6
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 6
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- 230000031700 light absorption Effects 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 4
- VBKISPPTGBOHFG-UHFFFAOYSA-N 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid propanoic acid Chemical compound N(CC(=O)O)C(CO)(CO)CO.C(CC)(=O)O VBKISPPTGBOHFG-UHFFFAOYSA-N 0.000 claims description 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 125000005638 hydrazono group Chemical group 0.000 claims description 4
- 238000001126 phototherapy Methods 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000006773 (C2-C7) alkylcarbonyl group Chemical group 0.000 claims description 3
- 125000006725 C1-C10 alkenyl group Chemical group 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- IGEIFKIBAFHEFY-JTQLQIEISA-N (2s)-2-[(2,4,6-trimethylphenyl)sulfonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NS(=O)(=O)C1=C(C)C=C(C)C=C1C IGEIFKIBAFHEFY-JTQLQIEISA-N 0.000 claims description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 2
- JBTYROWCCWPPOI-UHFFFAOYSA-N 2-(6-aminohexanoylamino)-2-[[[1-[3-(1H-imidazol-2-ylamino)propyl]indazole-5-carbonyl]amino]methyl]-3-oxobutanoic acid Chemical compound C(C)(=O)C(C(=O)O)(CNC(=O)C=1C=C2C=NN(C2=CC=1)CCCNC=1NC=CN=1)NC(CCCCCN)=O JBTYROWCCWPPOI-UHFFFAOYSA-N 0.000 claims description 2
- RFMMMVDNIPUKGG-UHFFFAOYSA-N Acetyl-Glu Chemical compound CC(=O)NC(C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-UHFFFAOYSA-N 0.000 claims description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 238000002725 brachytherapy Methods 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 238000002647 laser therapy Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- MYAJTCUQMQREFZ-UHFFFAOYSA-K tppts Chemical compound [Na+].[Na+].[Na+].[O-]S(=O)(=O)C1=CC=CC(P(C=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=C(C=CC=2)S([O-])(=O)=O)=C1 MYAJTCUQMQREFZ-UHFFFAOYSA-K 0.000 claims 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 7
- 125000005841 biaryl group Chemical group 0.000 claims 6
- 102100020873 Interleukin-2 Human genes 0.000 claims 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 229910014585 C2-Ce Inorganic materials 0.000 claims 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical group [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 35
- 229910021645 metal ion Inorganic materials 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 24
- 210000002889 endothelial cell Anatomy 0.000 description 22
- 239000002245 particle Substances 0.000 description 21
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 230000005298 paramagnetic effect Effects 0.000 description 16
- 229910052713 technetium Inorganic materials 0.000 description 16
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 210000005166 vasculature Anatomy 0.000 description 14
- 102000006495 integrins Human genes 0.000 description 13
- 108010044426 integrins Proteins 0.000 description 13
- 238000009007 Diagnostic Kit Methods 0.000 description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 12
- 231100000433 cytotoxic Toxicity 0.000 description 12
- 230000001472 cytotoxic effect Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000002872 contrast media Substances 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000002491 angiogenic effect Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 239000004005 microsphere Substances 0.000 description 10
- 102000000844 Cell Surface Receptors Human genes 0.000 description 9
- 108010001857 Cell Surface Receptors Proteins 0.000 description 9
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000005251 gamma ray Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000003573 thiols Chemical group 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002961 echo contrast media Substances 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000012216 imaging agent Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000003607 modifier Substances 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 5
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 5
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000002870 angiogenesis inducing agent Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910052702 rhenium Inorganic materials 0.000 description 5
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000002616 MRI contrast agent Substances 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 102000004207 Neuropilin-1 Human genes 0.000 description 4
- 108090000772 Neuropilin-1 Proteins 0.000 description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 150000003003 phosphines Chemical class 0.000 description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 4
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010036395 Endoglin Proteins 0.000 description 3
- 102000012085 Endoglin Human genes 0.000 description 3
- 102400001047 Endostatin Human genes 0.000 description 3
- 108010079505 Endostatins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 241001111421 Pannus Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- 150000002429 hydrazines Chemical class 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 2
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 2
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 2
- 125000005986 4-piperidonyl group Chemical group 0.000 description 2
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- 102000012936 Angiostatins Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102100038083 Endosialin Human genes 0.000 description 2
- 101710144543 Endosialin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108050001286 Somatostatin Receptor Proteins 0.000 description 2
- 102000011096 Somatostatin receptor Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- AIESRBVWAFETPR-UHFFFAOYSA-N cyclohexa-1,2,4,5-tetraene Chemical compound C1=C=CC=C=C1 AIESRBVWAFETPR-UHFFFAOYSA-N 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005597 hydrazone group Chemical group 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 150000002527 isonitriles Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000012285 ultrasound imaging Methods 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- PCWPQSDFNIFUPO-VDQKLNDWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-37,39,41,43,45,47,49-heptakis(2-hydroxyethoxy)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38,40,42,44,46,48-heptol Chemical compound OCCO[C@H]1[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O[C@H]5O[C@H](CO)[C@@H](O[C@H]6O[C@H](CO)[C@@H](O[C@H]7O[C@H](CO)[C@@H](O[C@H]8O[C@H](CO)[C@@H](O[C@H]1O[C@@H]2CO)[C@@H](O)[C@@H]8OCCO)[C@@H](O)[C@@H]7OCCO)[C@@H](O)[C@@H]6OCCO)[C@@H](O)[C@@H]5OCCO)[C@@H](O)[C@@H]4OCCO)[C@@H](O)[C@@H]3OCCO PCWPQSDFNIFUPO-VDQKLNDWSA-N 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 1
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical class OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 description 1
- QGKBSGBYSPTPKJ-UZMKXNTCSA-N 2,6-di-o-methyl-β-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC QGKBSGBYSPTPKJ-UZMKXNTCSA-N 0.000 description 1
- APIMXAGCLCGUGB-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-5-yl)acetate Chemical compound NC1=NC=C(CC(O)=O)S1 APIMXAGCLCGUGB-UHFFFAOYSA-N 0.000 description 1
- ZSXHABVLNSQDFP-UHFFFAOYSA-N 2-(dihydroxyamino)-2-phenylacetic acid;ethane-1,2-diamine Chemical compound NCCN.ON(O)C(C(O)=O)C1=CC=CC=C1 ZSXHABVLNSQDFP-UHFFFAOYSA-N 0.000 description 1
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 description 1
- CUJVBAPGYBSBHJ-YWBSARSQSA-N 2-[[(1R,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21R,23R,25R,26R,28R,30R,31R,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,38,40,42-tetrakis(carboxymethoxy)-10,15-bis(carboxymethoxymethyl)-37,39,41,43,44,45,46,47,48,49-decahydroxy-20,25,30,35-tetrakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]acetic acid Chemical compound OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCC(O)=O)O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]1[C@H](OCC(O)=O)[C@H]2O)[C@H](O)[C@H]5OCC(O)=O)[C@H](O)[C@H]4OCC(O)=O)[C@H](O)[C@H]3OCC(O)=O CUJVBAPGYBSBHJ-YWBSARSQSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-M 2-hydroxyisobutyrate Chemical compound CC(C)(O)C([O-])=O BWLBGMIXKSTLSX-UHFFFAOYSA-M 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical class N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- LOTVQXNRIAEYCG-UHFFFAOYSA-N 3-hydroxy-2-(hydroxymethyl)-2-[hydroxymethyl(methyl)amino]propanoic acid Chemical compound OCN(C)C(CO)(CO)C(O)=O LOTVQXNRIAEYCG-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- CYBHWCLUGRHMCK-UHFFFAOYSA-N 4aH-carbazole Chemical compound C1=CC=C2C3C=CC=CC3=NC2=C1 CYBHWCLUGRHMCK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- UYFXDTIRCJKJGJ-UHFFFAOYSA-N OS(=O)(=O)C1=CC=CC=C1C=NNC1=CCC(=C=O)C=N1 Chemical compound OS(=O)(=O)C1=CC=CC=C1C=NNC1=CCC(=C=O)C=N1 UYFXDTIRCJKJGJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000191761 Sida cordifolia Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- DDPGACIVVDXPCY-UHFFFAOYSA-N [As].[AsH3] Chemical compound [As].[AsH3] DDPGACIVVDXPCY-UHFFFAOYSA-N 0.000 description 1
- VYRDHRYMAZWQJH-UHFFFAOYSA-N [P].P Chemical compound [P].P VYRDHRYMAZWQJH-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- JVFGXECLSQXABC-UHFFFAOYSA-N ac1l3obq Chemical compound O1C(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC(C(O)C2O)C(COCC(O)C)OC2OC(C(C2O)O)C(COCC(C)O)OC2OC2C(O)C(O)C1OC2COCC(C)O JVFGXECLSQXABC-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- GFXMFSCCEVADLF-UHFFFAOYSA-N n-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]acetamide Chemical compound S1C(NC(=O)C)=NC=C1SCC1=NC=C(C(C)(C)C)O1 GFXMFSCCEVADLF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000004624 phenarsazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3[As]=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 125000003367 polycyclic group Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention provides novel __ pharmaceuticals useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient.
- the invention is also directed to novel pharmaceutical compositions and combination therapy comprising a compound of the invention or a pharmaceutically acceptable salt thereof, and at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent.
- the invention is directed to novel pharmaceutical compositions and combination therapy comprising a compound of the invention or a pharmaceutically acceptable salt thereof, and a photosensitizing agent.
- the pharmaceuticals are comprised of a targeting moiety that binds to the vitronectin receptor that is expressed in tumor vasculature, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
- the therapeutically effective radioisotope emits a gamma ray or alpha particle sufficient to be cytotoxic.
- the imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
- Cancer is a major public health concern in the United States and around the world. It is estimated that over 1 million new cases of invasive cancer will be diagnosed in the United States in 1998. The most prevalent forms of the disease are solid tumors of the lung, breast, prostate, colon and rectum. Cancer is typically diagnosed by a combination of in vitro tests and imaging procedures .
- the imaging procedures include X-ray computed tomography, magnetic resonance imaging, ultrasound imaging and radionuclide scintigraphy.
- a contrast agent is administered to the patient to enhance the image obtained by X-ray CT, MRI and ultrasound, and the administration of a radiopharmaceutical that localizes in tumors is required for radionuclide scintigraphy.
- Treatment of cancer typically involves the use of external beam radiation therapy and chemotherapy, either alone or in combination, depending on the type and extent of the disease.
- a number of chemotherapeutic agents are available, but generally they all suffer from a lack of specificity for tumors versus normal tissues, resulting in considerable side-effects.
- the effectiveness of these treatment modalities is also limited, as evidenced by the high mortality rates for a number of cancer types, especially the more prevalent solid tumor diseases. More effective and specific treatment means continue to be needed.
- metallopharmaceutical that localizes specifically in the tumor by binding to a receptor expressed only in tumors or expressed to a significantly greater extent in tumors than in other tissue.
- the location of the metallopharmaceutical could then be detected externally either by its imageable emission in the case of certain radiopharmaceuticals or by its effect on the relaxation rate of water in the immediate vicinity in the case of magnetic resonance imaging contrast agents .
- This tumor specific metallopharmaceutical approach can also be used for the treatment of cancer when the metallopharmaceutical is comprised of a particle emitting radioisotope.
- the radioactive decay of the isotope at the site of the tumor results in sufficient ionizing radiation to be toxic to the tumor cells.
- the specificity of this approach for tumors minimizes the amount of normal tissue that is exposed to the cytotoxic agent and thus may provide more effective treatment with fewer side-effects.
- radionuclide labeled monoclonal antibodies, antibody fragments and other proteins or polypeptides that bind to tumor cell surface receptors have centered on the use of radionuclide labeled monoclonal antibodies, antibody fragments and other proteins or polypeptides that bind to tumor cell surface receptors .
- the specificity of these radiopharmaceuticals is frequently very high, but they suffer from several disadvantages.
- due to their molecular weight do not extravasate readily at the site of the tumor and then only slowly diffuse through the extravascular space to the tumor cell surface. This results in a very limited amount of the radiopharmaceutical reaching the receptors and thus very low signal intensity in imaging and insufficient cytotoxic effect for treatment.
- Angiogenesis is the prcoess by which new blood vessels are formed from pre-existing capillaries or post capillary venules; it is an important component of a variety of physiological processes including ovulation, embryonic development, wound repair, and collateral vascular generation in the myocardium. It is also central to a number of pathological conditions such as tumor growth and metastasis, diabetic retinopathy, and macular degeneration.
- the process begins with the activation of existing vascular endothelial cells in response to a variety of cytokines and growth factors. Tumor released cytokines or angiogenic factors stimulate vascular endothelial cells by interacting with specific cell surface receptors for the factors.
- the activated endothelial cells secrete enzymes that degrade the basement membrane of the vessels.
- the endothelial cells then proliferate and invade into the tumor tissue.
- the endothelial cells differentiate to form lumens, making new vessel offshoots of pre-existing vessels.
- the new blood vessels then provide nutrients to the tumor permitting further growth and a route for metastasis .
- endothelial cell proliferation is a very slow process, but it increases for a short period of time during embryogenesis, ovulation and wound healing. This temporary increase in cell turnover is governed by a combination of a number of growth stimulatory factors and growth suppressing factors. In pathological angiogenesis, this normal balance is disrupted resulting in continued increased endothelial cell proliferation.
- proangiogenic factors include basic fibroblast growth factor (bFGF) , angiogenin, TGF- alpha, TGF-beta, and vascular endothelium growth factor (VEGF) .
- bFGF basic fibroblast growth factor
- angiogenin angiogenin
- TGF- alpha TGF-beta
- VEGF vascular endothelium growth factor
- interferon-alpha, interferon-beta and thro bospondin are examples of angiogenesis suppressors .
- Integrins are a diverse family of heterodimeric cell surface receptors by which endothelial cells attach to the extracellular matrix, each other and other cells.
- the integrin ⁇ v ⁇ 3 is a receptor for a wide variety for a wide variety of extracellular matrix proteins with an exposed tripeptide Arg-Gly-Asp moiety and mediates cellular adhesion to its ligand: vitronectin, fibronectin, and fibrinogen, among others.
- the integrin ⁇ 3 is minimally expressed on normal blood vessels, but is significantly upregulated on vascular cells within a variety of human tumors.
- the role of the ⁇ v ⁇ 3 receptors is to mediate the interaction of the endothelial cells and the extracellular matrix and facilitate the migration of the cells in the direction of the angiogenic signal, the tumor cell population.
- Angiogenesis induced by bFGF or TNF-alpha depend on the agency of the integrin oc v ⁇ 3 , while angiogenesis induced
- VEGF vascular endothelial growth factor
- Angiogenic factors interact with endothelial cell surface receptors such as the receptor tyrosine kinases EGFR, FGFR, PDGFR, Fl -1/KDR, Flt-1, Tek, tie, neuropilin-1, endoglin, endosialin, and Axl .
- the receptors Flk-1/KDR, neuropilin-1, and Flt-1 recognize VEGF and these interactions play key roles in VEGF- induced angiogenesis.
- the Tie subfamily of receptor tyrosine kinases are also expressed prominently during blood vessel formation.
- angiostatin is a 38 kDa fragment of plasminogen that has been shown in animal models to be a potent inhibitor of endothelial cell proliferation.
- Endostatin is a 20 kDa C-terminal fragment of collagen XVIII that has also been shown to be a potent inhibitor.
- Endostatin Systemic therapy with endostatin has been shown to result in strong anti-tumor activity in animal models.
- human clinical trials of these two chemotherapeutic agents of biological origin have been hampered by lack of availability .
- Another approach to anti-angiogenic therapy is to use targeting moieties that interact with endothelial cell surface receptors expressed in the angiogenic vasculature to which are attached chemotherapeutic agents.
- Burrows and Thorpe Proc. Nat. Acad. Sci, USA, 1993, 90, 8996-9000
- the antibody was raised against an endothelial cell class II antigen of the major histocompatibility complex and was then conjugated with the cytotoxic agent, deglycosylated ricin A chain. The same group (Clin. Can.
- the receptor targets for the radiopharmaceutical compounds, used in this method of treatment are expressed on the luminal side of tumor vessels, there is no requirement that these compounds traverse the capillary bed and bind to the tumor itself.
- angiogenesis-targeted therapeutic radiopharmaceuticals and an anti-cancer agents or a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
- Photodynamic therapy has also been used in the treatment of cancer. Photodynamic therapy involves the administration of a photosensitive agent and subsequent irradiation with light to excite the photosensitizer, thus producing a cytotoxic effect. Spears, U.S. Pat. No.
- the photosensitizers used are capable of localizing in malignant cells, either by natural tendency or because they have been intentionally targeted to a specific type of tissue, or both. When irradiated, they may be capable of fluorescing and, thus, may also be useful in diagnostic methods related to detecting target tissue.
- the photosensitizer has the capacity, when irradiated with light at a wavelength which the compound absorbs, of causing a cytotoxic effect against whatever cells or other tissue in which the photosensitizer has localized.
- a photosensitizer agent having a characteristic light absorption waveband is first administered to the patient, typically either orally or by injection.
- Abnormal tissue in the body is known to selectively absorb certain photosensitizer agents to a much greater extent than normal tissue. More effective selectivity can be achieved using a photoreactive agent that is bound to an antibody, which links with antigens on targeted cell .
- the cancerous or abnormal tissue that has absorbed or linked with the photosensitizer dye is then destroyed by administering light of an appropriate wavelength or waveband corresponding to the absorption wavelength or waveband of the photosensitizer agent .
- Photosensitizing agents such as Photofrin, a haematoporphyrin derivative, are known.
- Photosensitizers therapy and detection of malignant tumours. Photochem. Photobiol . , 45, 879-889, and Boyle R. W. and D. David (1996) Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 64, 469-485)
- Rodgers,et al . United States Patent No.
- 6,225,333 discloses treating cancers with a variety of photosensitizing agents for example naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; including porphyins; chlorins;, phthalocyanines; napthalocyanines; coumarins and psoralens. Furthermore, Mazur, et al . , United States Patent No.
- 6,229,0408 discloses a method for treatment of solid tumors by photodynamic therapy comprising administering a photosensitizer selected from the group consisting of : 1,3,4, 6-tetrahydroxyhelianthrone ; 1,3,4, 6-tetramethoxyhelianthrone; 10, 13-dimethyl- 1,3,4, 6-tetrahydroxyhelianthrone; 10, 13- di (methoxycarbonyl) -1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino-3, 4-dimethoxy-helianthrone; 1,6-di- N-butylamino-3 , 4-dimethoxy-lO, 13-dimethyl-helianthrone; 1, 6-di- (N-hydroxyethylamino) -3 , 4-dimethoxy-helianthrone; 2 , 5-dibromo-l, 3 , 4, 6-tetrahydroxyhelianthrone; and 2,5- dibromo-10
- a light-emitting balloon catheter may be used or alternatively, a form of "liquid light” may be injected into the vascular tree such that the "liquid light”, perfuses the vasculature at the target site. Spears, U.S. Pat. No. 4,512,762. Alternatively,
- the targeted tissues are visually located by imaging the treatment site through a fiber optic system so that light from a laser source can be accurately directed through the optical fiber to destroy the abnormal tissue. Even when the internal treatment site is accessible through natural body orifices, an endoscope is usually required to visualize the targeted tissue and accurately direct the light therapy administered to the treatment site.
- Chen, United States Patent No. 6,210,425 discloses an apparatus and a method to identify an internal treatment site within a patient's body for administration of light therapy and treatment of the site.
- a photosensitizer agent as part of photodynamic therapy
- an angiogenesis-targeted therapeutic radiopharmaceutical and an anti-cancer agent or a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
- RA rheumatoid arthritis
- cardiovascular diseases need to be improved, including restenosis, atherosclerosis, myocardial reperfusion injury, and myocardial ischemia, stunning or infarction. It has recently been determined that in all of these disease conditions, the integrin receptor ⁇ v ⁇ 3 plays an important role.
- neointimal hyperplasia and ultimate reocclusion is caused by aggressively proliferating vascular smooth muscle cells that express v ⁇ 3 .
- Atherosclerosis proceeds from an intial endothelial damage that results in the recruitment and subintimal migration of monocytes at the site of the injury. Growth factors are released which induce medial smooth muscle cells to proliferate and migrate to the intimal layer.
- the migrating smooth muscle cells express v ⁇ 3 .
- neutrophil transmigration is integrin dependent and the integrins moderate initial infiltration into the viable border zone.
- the induction of o 5 ⁇ 1 , 4 ⁇ ⁇ and ⁇ v ⁇ 5 in infiltrating neutrophils occurs within 3 to 5 hours after reperfusion as neutrophils move from the border zone to the area of necrosis. (Circulation, 1999, 100, 1-275)
- Acute or chronic occlusion of a coronary artery is known to result in angiogenesis in the heart as native collateral vessels are recruited to attempt to relieve the ischemia.
- Cardiac angiogenesis has been associated with increased expression of the growth factors VEGF and FGF and the upregulation of the growth factor receptors flt-1 and flk-1/KDR. (Drugs, 1999, 58, 391-396)
- the vitronectin receptor binding compounds target the radioisotope to the tumor neovasculature.
- the beta or alpha-particle emitting radioisotope emits a cytotoxic amount of ionizing radiation which results in cell death. The penetrating ability of radiation obviates the requirement that the cytotoxic agent diffuse or be transported into the cell to be cytotoxic.
- These pharmaceuticals comprise a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a radioisotope that emits cytotoxic radiation (i.e., beta particles, alpha particles and Auger or Coster-Kronig electrons) .
- cytotoxic radiation i.e., beta particles, alpha particles and Auger or Coster-Kronig electrons
- the radiopharmaceuticals of the present invention that emit cytotoxic radiation could be used to destroy the new angiogenic vasculature that results and thus treat the disease.
- kits and therapeutic radiopharmacutical compositions for use in combination therapy comprising a radiopharmacutical of the invention and at least one agents selected from the group consisting of an anti- cancer agent and a radiosensitizer agent.
- kits and therapeutic radiopharmacutical compositions for use in combination therapy comprising a radiopharmacutical of the invention and a photosensitising agent.
- It is another object of the present invention to provide a method of treating cancer comprising administering to a patient in need of such treatment a therapeutic radiopharmaceutical composition of the invention in combination with photodynamic therapy.
- imaging agents comprised of vitronectin receptor binding compounds conjugated to an imageable moiety, such as a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent .
- imageable moiety such as a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
- imaging agents are useful for imaging tumor neovasculature, therapeutic angiogenesis interventions in the heart, natural angiogenic processes in response to acute or chronic coronary vessel occlusion, restenosis post-angioplasty, atherosclerosis and plaque formation, and reperfusion injury.
- These compounds are comprised of a non-peptide indazole containing targeting moiety that binds to a receptor that is upregulated during angiogenesis or during cardiovascular diseases, Q, an optional linking group, L n , and a metal chelator or bonding moiety, C -
- the compounds may have one or more protecting groups attached to the metal chelator or bonding moiety. The protecting groups provide improved stability to the reagents for long-term storage and are removed either immediately prior to or concurrent with the synthesis of the radiopharmaceuticals.
- the compounds of the present invention are comprised of a peptide or peptidomimetic targeting moiety that binds to a receptor that is upregulated during angiogenesis or during cardiovascular diseases, Q, an optional linking group, L n , and a surfactant, S f .
- the pharmaceuticals of the present invention may be used for diagnostic and/or therapeutic purposes.
- Diagnostic radiopharmaceuticals of the present invention are pharmaceuticals comprised of a diagnostically useful radionuclide (i.e., a radioactive metal ion that has imageable gamma ray or positron emissions) .
- Radiopharmaceuticals of the present invention are pharmaceuticals comprised of a therapeutically useful radionuclide, a radioactive metal ion that emits ionizing radiation such as beta particles, alpha particles and Auger or Coster-Kronig electrons .
- the pharmaceuticals comprising a gamma ray or positron emitting radioactive metal ion are useful for imaging tumors and by gamma scintigraphy or positron emission tomography.
- the pharmaceuticals comprising a gamma ray or positron emitting radioactive metal ion are also useful for imaging therapeutic angiogenesis, natural angiogenic processes in response to acute or chronic coronary vessel occlusion, restenosis post- angioplasty, atherosclerosis and plaque formation, and reperfusion injury by gamma scintigraphy or positron emission tomography.
- the pharmaceuticals comprising a particle emitting radioactive metal ion are useful for treating cancer by delivering a cytotoxic dose of radiation to the tumors.
- the pharmaceuticals comprising a particle emitting radioactive metal ion are also useful for treating rheumatoid arthritis by destroying the formation of angiogenic vasculature.
- the pharmaceuticals comprising a paramagnetic metal ion are useful as magnetic resonance imaging contrast agents.
- the pharmaceuticals comprising one or more X-ray absorbing or "heavy" atoms of atomic number 20 or greater are useful as X-ray contrast agents.
- the pharmaceuticals comprising a microbubble of a biocompatible gas, a liquid carrier, and a surfactant microsphere, are useful as ultrasound contrast agents.
- the present invention provides a kit for treating cancer, comprising a compound of the formula (I) and at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound of the formula (I) is: ( Q)d-Ln-Ch or ( Q)d-Ln- ( Ch ) d'
- X 2d is N, CH, or C- W d - X d - Y d
- X 3d is N, CR lld , or C-W d -X d -Y d
- X d is N or CR lld ;
- R ld is selected from: R lde , C ⁇ -CQ alkyl substituted with 0-1 R 15d or 0-1 R 21d , C 3 -C 6 alkenyl substituted with
- Rlde ig selected from:
- a ld and B ld are independently -CH 2 - or -N(R 3d )-;
- J d , K d , L d and M d are independently selected from
- R 2d is selected from: H, C ⁇ C 6 alkyl, (C ⁇ -C 6 alkyl) carbonyl, (C ⁇ C 6 alkoxy) carbonyl; (C ⁇ C 6 alkyl) aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 eyeloalkylalkyl, aryl, heteroaryl ( C -CQ alkyl) carbonyl, heteroarylcarbonyl , aryl(C ⁇ -C 6 alkyl)-, (Ci-Cg alkyl) carbonyl-, arylcarbonyl , C 1 -C 6 alkylsulfonyl, arylsulfonyl, aryl(C ⁇ -C 6 alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (C 1 -C 6 alkyl) sulfonyl, aryloxycarbonyl, and
- R and R 5d are independently selected from: H, C 1 -C 4 alkoxy, NR 2d R 3d , halogen, N0 2/ - CN, CF 3 , C ⁇ -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-C ⁇ alkyl)-, (Ci-C ⁇ alkyl) carbonyl, (Ci-C ⁇ alkoxy) carbonyl, and arylcarbonyl, or
- R d and R 5d when substituents on adjacent atoms, R d and R 5d can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C 3. -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , and N0 ;
- U d is selected from: -(CH 2 ) n d -,
- Q d is selected from 1, 2 -cycloalkyl ene, 1, 2 -phenyl ene, 1, 3-phenylene, 1, 4 -phenyl ene, 2 , 3-pyridinylene, 3 , 4-pyridinylene, 2 , 4-pyridinylene, and 3,4- pyridazinylene;
- R 6d is selected from: H, C1-C4 alkyl, and benzyl;
- R 7d and R 8d are independently selected from: H, C1-C6 alkyl, C3-C7 cycloalkyl, C4-C11 cycloalkylalkyl, aryl, aryl (C -C6 alkyl)-, and heteroaryl (CQ-C6 alkyl) - ;
- R ll d ig selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2d R 3d , C 1 -C 4 alkyl substituted with 0-1 R 21d , C 1 -C 4 alkoxy substituted with 0-1 R 21d , aryl substituted with 0-1 R 21d , aryl(C ⁇ -C 6 alkyl)- substituted with
- X d is -C(R 12d ) (R 14d )-C(R 12d ) (R 15d )-; or alternatively, W d and X d can be taken together to be
- R 12d is selected from H, halogen, C1-C 6 alkyl, C 2 -C 6 alkenyl, C -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl ) carbonyl , aryl, and aryl (C 1 -C 6 alkyl)-;
- R 13d is selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkylmethyl, and aryl(C ⁇ -C 6 alkyl)-;
- R 1 d is selected from:
- Ci-Cg alkylthio (C1-C6 alkyl)-, aryl(C ⁇ -C ⁇ o alkylthioalkyl) -, aryl(C ⁇ -C ⁇ o alkoxyalkyl ) - , C 1 -C 10 alkyl, C 1 -C 0 alkoxyalkyl, C -C 6 hydroxyalkyl , C -C ⁇ o alkenyl, C -C ⁇ o alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl(C ⁇ -C 6 alkyl)-, heteroaryl (Ci-Cg alkyl)-, aryl, heteroaryl, C0 R 17d , C( 0)R 17d , and CONR 17d R 20d , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted or
- R l5d is selected from:
- R 16d C 1 -C 10 alkyl, C ⁇ -C 10 alkoxyalkyl,
- C l -Cio alkylaminoalkyl, C 1 -C 10 dialkylaminoalkyl, (C 1 -C 10 alkyl) carbonyl, aryl (C 1 -C 6 alkyl) carbonyl, C 1 -C 10 alkenyl, C 1 -C1 0 alkynyl ,C 3 ⁇ C ⁇ o cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl (Ci-Ce alkyl)-, heteroaryl (C 1 -C 6 alkyl)-, aryl, heteroaryl, C0 R 17d , C( 0)R 17d , CONR 17d R 20d , S0 2 R 17d , and SO 2 NR 17d R 20 , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R lld ;
- Y d is selected from: -COR 19d , -SO 3 H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , - CONHS0 R 17d , -CONHS0 2 NHR 17d , -NHCOCF 3 , - NHCONHS0 R 17d , -NHS0 2 R 17d , -OP0 3 H 2 , -OSO3H , -PO3H2 , SO3H , -S0 2 NHCOR 17d , -S0 2 NHC0 2 R 17d ,
- R 1 d is selected from: c l ⁇ C l ⁇ alkyl optionally substituted with a bond to L n , C 3 -C 11 cycloalkyl optionally substituted with a bond to L n , aryl(C ⁇ -Cg alkyl)- optionally substituted with a bond to L n , (Ci-C ⁇ alkyl) aryl optionally substituted with a bond to L n , heteroaryl (Ci-C ⁇ alkyl)- optionally substituted with a bond to L n , (Ci-C ⁇ alkyl) heteroaryl optionally substituted with a bond to L n , biaryl (C 3 .-C 6 alkyl)- optionally substituted with a bond to L n , heteroaryl optionally substituted with a bond to L n , aryl optionally substituted with a bond to L n , biaryl optionally substituted with a bond to L n , and
- Rl8d i s selected from: -H,
- R 19d is selected from: hydroxy, C 1 -C 10 alkyloxy,
- R 20 d ig selected from: H, Ci-Cg alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-C ⁇ alkyl) -, and heteroaryl (C 1 -C 5 alkyl) - ;
- R 21d is selected from : COOH and NR 6d ;
- d m is 0-4 ;
- d n is 0-4 ;
- d t is 0-4 ;
- d P is 0-2 ;
- n and m are chosen such that the value of n plus d d m is greater than one unless U is d d d -(CH 2 ) t Q (CH 2 ) m -;
- Q is a peptide selected from the group:
- R 1 is L-valine, D-valine or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
- R 2 is L-phenylalanine, D-phenylalanine, D-1-naphthylalanine, 2-aminothiazole-4-acetic acid or tyrosine, the tyrosine optionally substituted on the hydroxy group with a bond to L n ;
- R 3 is D-valine
- R 4 is D-tyrosine substituted on the hydroxy group with a bond to L n ;
- R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine;
- At least one Q is a compound of Formula (la) or (lb);
- d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
- d' is 1-100
- L n is a linking group having the formula:
- aa is independently at each occurrence an amino acid
- Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
- R 11 is independently selected at each occurrence from the group: H, -OPO3H2, alkyl substituted with 0-1
- R 12 is a bond to C h ;
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 , S, SH, S(Pg), 0, OH, PR 13 , PR 13 R 14 , P(0)R 15 R 16 , and a bond to L n ;
- E is a bond, CH, or a spacer group independently selected at each occurrence from the group: C_-C ⁇ o alkyl substituted with 0-3 R ⁇ 7 , aryl substituted with 0-3 RI "7 , C 3 -- 10 cycloalkyl substituted with 0-3
- heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and
- R 13 and R- ⁇ - 4 are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R- 1 - 7 , aryl substituted with 0-3 R 17 , C ⁇ _ ⁇ o cycloalkyl substituted with 0-3 R ⁇ 7 , heterocyclo-Ci-io alkyl substituted with 0-3 R ⁇ 7 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C ⁇ -io aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R ⁇ 7 , C ⁇ _ ⁇ o alkyl-Cg-io aryl- substituted with 0-3 R- ⁇ 7 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 17 , and an electron, provided that when one of R
- R 15 and R 15 are each independently selected from the group: a bond to L n , -OH, Ci-Cio alkyl substituted with 0-3 R 17 , Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 - 10 cycloalkyl substituted with 0-3 R ⁇ 7 , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R ⁇ , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C ⁇ -io aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 7 , C ⁇ _ ⁇ o alkyl-C 6 _ ⁇ o aryl- substituted with 0-3 R 17 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17
- R 1 ⁇ , Ri8a ; anc j R 19 are independently selected at each occurrence from the group: a bond to L n , H, C1-C6 alkyl, phenyl, benzyl, C1-C6 alkoxy, halide, nitro, cyano, and trifluoromethyl;
- Pg is a thiol protecting group
- R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
- R 22 and R 23 are independently selected from the group: H, R 24 , C1-C10 alkyl substituted with 0-3 R 24 , C2-C10 alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 24 , and C 3 -. 10 carbocycle substituted with 0-3 R 24 ;
- R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
- a and b indicate the positions of optional double bonds and n is 0 or 1;
- R 25 , R 25a , and R 26 are each independently selected at each occurrence from the group: hydrogen and Ci-C ⁇ alkyl .
- the present invention provides a kit according to Embodiment 1 wherein R lde is selected from:
- a ld and B ld are independently -CH - or -N(R 3d )-;
- J , K , L and M are independently selected from:
- R 2d i s selected from: H, Ci-Ce alkyl, (Ci-C ⁇ alkyl ) carbonyl , (Ci-C ⁇ alkoxy) carbonyl, Ci-C ⁇ alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-C ⁇ alkyl) carbonyl, heteroarylcarbonyl, aryl (Ci-C ⁇ alkyl)-, (Ci-C ⁇ alkyl) carbonyl , arylcarbonyl, alkylsulfonyl, arylsulfonyl, a yl(C ⁇ -C 6 alkyl) sulfonyl, heteroarylsulfonyl , heteroaryl (C ⁇ -C 6 alkyl) sulfonyl, arylox carbony
- R 3d is selected from: H, Ci-C ⁇ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-C ⁇ alkyl)-, and heteroaryl (Ci-C ⁇ alkyl)-,-
- R 4d and R 5d are independently selected from: H, C 1 -C 4 alkoxy, NR 2d R 3d , halogen, N0 2 , CN, CF 3 , C ⁇ -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 1 1 cycloalkylalkyl, aryl, aryl(C ⁇ -Cg alkyl)-, C 2 -C 7 alkylcarbonyl, and arylcarbonyl;
- R d and R 5d can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; d U is selected from: d -(CH 2 ) n -,
- d Q is selected from 1, 2-phenylene, 1, 3-phenylene, 2,3- pyridinylene, 3 , 4-pyridinylene, and 2,4- pyridinylene;
- R 6d is selected from: H, C 1 -C 4 alkyl, and benzyl;
- R 7d and R 8d are independently selected from: H, Ci-C ⁇ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(C ⁇ -C 6 alkyl)-, and heteroaryl (Co-Cg alkyl)-,.
- X is -C(R 12d ) (R 1 d )-C(R 12 ) (R 15d )-;
- R 12d is H or C ⁇ -C 6 alkyl ;
- d Y is selected from:
- d is selected from 1, 2, 3, 4, and 5;
- aa is independently at each occurrence an amino acid
- Z is selected from the group: aryl substituted with 0-1 R 10 , C 3 - 10 cycloalkyl substituted with 0-1 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 10 ;
- k is 0 or 1; s is selected from 0, 1, 2, 3, 4, and 5; s' is selected from 0, 1, 2, 3, 4, and 5; s" is selected from 0, 1, 2, 3, 4, and 5; t is selected from 0, 1, 2, 3, 4, and 5;
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 / S/ SH s(Pg), OH, and a bond to L n ;
- E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-C o alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 7 , C 3 -- 10 cycloalkyl substituted with 0-3
- R 1 and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
- R 13 and R 14 are each independently selected from the group: a bond to L n , hydrogen, C1-C10 alkyl substituted with 0-3 R 7 , aryl substituted with 0-3
- R 17 a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 14 is an electron, then the other is also an electron;
- R 18 , R 18a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, and C1-C6 alkyl;
- R 20 and R 21 are independently selected from the group:
- R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
- R 22 and R 23 are independently selected from the group: H, and R 24 ;
- R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
- R 25 is independently selected at each occurrence from the group: H and C1-C3 alkyl.
- the present invention provides a kit according to Embodiment 1, wherein:
- R lde is selected from:
- heterocycles are optionally substituted with 0-2 substituents selected from the group: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Ci- C ⁇ alkyl, and C 3 -C 7 cycloalkyl;
- R is selected from: Ci-C ⁇ alkyl, C3-C7 cycloalkyl, C4-
- R 10 d ig selected from: H, R lde , C1-C4 alkoxy substituted with 0-1 R 21d , halogen, C0 2 R 17d , CONR 17d R 20d , C ⁇ -C 6 alkyl substituted with 0-1 R 15d or 0-1 R 21d , C 3 -C7 cycloalkyl substituted with 0-1 R 15d or 0-1 R 21d ,
- i ⁇ d e ig selected from: H, C1-C4 alkoxy substituted with 0-1 R 21d , halogen, C0 2 R 17d , CONR 17d R 20d , C ⁇ -C 6 alkyl substituted with 0-1 R 15d or 0-1 R 21d , C3-C7 cycloalkyl substituted with 0-1 R 15d or 0-1 R 21d , C4-C11 cycloalkylalkyl substituted with 0-1 R 15d or 0-1 R 21d , and aryl(C ⁇ -C 6 alkyl)- substituted with 0-
- X is -CH (R 1 d ) -CH (R 15d ) - ;
- R 13 is H or CH 3 ;
- R 1 d is selected from:
- Ci-Cio alkyl, aryl, or heteroaryl wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, aryl , halo , cyano , amino , CF 3 , and N0 ;
- R 15d is H or R 16d ;
- Y is -COR 19d ;
- R l9d ig selected from: hydroxy, C 1 -C 10 alkoxy, methylcarbonyloxymethoxy- , ethylcarbonyloxymethoxy- , t-butylcarbonyloxymethoxy-, cyclohexylcarbonyloxymethoxy- , 1- (methylcarbonyloxy) ethoxy-, 1- (ethylcarbonyloxy) ethoxy-, 1- (t-butylcarbonyloxy) ethoxy-, 1- (cyclohexylcarbonyloxy) ethoxy- , i-propyloxycarbonyloxymethoxy- , t-butyloxycarbonyloxymethoxy- , 1- (i-propyloxycarbonyloxy) ethoxy- , 1- (cyclohexyloxycarbonyloxy) ethoxy- 1- (t-butyloxycarbonyloxy-, dimethylaminoethoxy- ,
- R 20d is H or CH 3 ;
- a 1 is selected from the group: OH, and a bond to L n ;
- a 2 , A 4 , and A 6 are each N;
- a 3 , A 5 , and A 8 are each OH;
- a 7 is a bond to L n or NH-bond to L n ;
- E is a C2 alkyl substituted with 0-1 R 17 ;
- R 17 0; alternatively, C h is
- a 1 is selected from the group: OH and a bond to L n ;
- a 2 , A 3 and A 4 are each N;
- a 5 , A 6 and A 8 are each OH;
- a 7 is a bond to L n ;
- E is a C2 alkyl substituted with 0-1 R 17 ;
- a 2 is NHR 13 ;
- R 13 is a heterocycle substituted with R 17 , the heterocycle being selected from pyridine and pyrimidine;
- R 18 is a bond to L n ;
- R 24 is selected from the group: -C0 2 R 25 , -OR 25 , -SO 3 H, and -N(R 25 ) ; and,
- R 25 is independently selected at each occurrence from the grou : hydrogen and methyl .
- the present invention provides a kit according to Embodiment 1, wherein:
- Rlde ig selected from:
- heterocycles are optionally substituted with 0-2 substituents selected from the group: NH 2 , halogen, N0 2 , CN, CF 3 , C 1 -C 4 alkoxy, Ci- C ⁇ alkyl, and C 3 -C 7 cycloalkyl.
- the present invention provides a kit according to Embodiment 1, wherein the compound of formula (I) is selected from the group :
- the present invention provides a kit according to Embodiment 1, wherein the kit further comprises one or more ancillary ligands and a reducing agent.
- the present invention provides a kit according to Embodiment 6 , wherein the ancillary ligands are tricine and TPPTS .
- the present invention provides a kit according to Embodiment 6, wherein the reducing agent is tin (II).
- the present invention provides a kit according to Embodiment 1, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, is
- the present invention provides a kit according to Embodiment 1, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, is
- the present invention provides a kit according to Embodiment 1 wherein the anti-cancer agent is selected from the group consisting of oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, and formestane.
- the anti-cancer agent is selected from the group consisting of oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, and formestane.
- the present invention provides a kit according to Embodiment 1 wherein the anti-cancer agent is selected from the group consisting of interferon-alpha, interferon-2 alpha, interferon- beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2 , denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.
- the anti-cancer agent is selected from the group consisting of interferon-alpha, interferon-2 alpha, interferon- beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2 , denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.
- the present invention provides a kit according to Embodiment 1, wherein radiosensitizer agent is selected from the group consiting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl ) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine- 1,4-dioxide, N- (2-hydroxyethyl) -2-nitroimidazole-l- acetamide, 1- (2-nitroimidazol-l-yl) -3- (1-piperidinyl) - 2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1- aziridino) -2-propanol .
- radiosensitizer agent is selected from the group consiting of 2- (3-nitro-l, 2 , 4-triazol-l-yl)
- the present invention provides a therapeutic radiopharmaceutical composition
- a therapeutic radiopharmaceutical composition comprising at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent, or a pharmaceutically acceptable ⁇ salt thereof, and a radiopharmaceutical comprising: a) a radioisotope; b) a chelator capable of chelating the radioisotope; and c) a targeting moiety; wherein the targeting moiety is bound to the chelator through 0-1 linking groups, and the targeting moiety is a indazole nonpeptide that binds to a receptor that is upregulated during angiogenesis.
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 14, wherein the radiopharmaceutical comprises: a) a radioisotope selected from the group 3 3 P, 125j
- X ld is N, CH, C-W d -X d -Y , or C-L n ;
- X 2d is N, CH, or C-W d -X d -Y d ;
- X 3d is N, CR lld , or C-W d -X d -Y d ;
- X d is N or CR lld ;
- R ld is selected from: R lde , Ci-C ⁇ alkyl substituted with 0-1 R 15d or 0-1 R 21d , C 3 -C 6 alkenyl substituted with
- R lde is selected from:
- a ld and B ld are independently -CH 2 - or -N(R 3d )-;
- J , K d , L d and M d are independently selected from
- 2d i s selected from: H, Ci-C ⁇ alkyl, (C -C ⁇ alkyl ) carbonyl , (Ci-C ⁇ alkoxy) carbonyl; (Ci-C ⁇ alkyl ) aminocarbonyl , C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (C ⁇ -C ⁇ alkyl) carbonyl, heteroarylcarbonyl , aryl(C ⁇ -C ⁇ alkyl)-, (Ci-C ⁇ alkyl) carbonyl-, arylcarbonyl, Ci-C ⁇ alkylsulfonyl, arylsulfonyl, aryl(C -C ⁇ alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-C ⁇ alkyl) sulf
- R d and R 5d are independently selected from: H, C 1 -C 4 alkoxy, NR 2d R 3d , halogen, N0 2 , CN, CF 3 , C ⁇ -C 6 alkyl, C 3 ⁇ C ⁇ alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(C ⁇ -C ⁇ alkyl)-, (Ci-C ⁇ alkyl) carbonyl, (Ci-C ⁇ alkoxy) carbonyl, and arylcarbonyl, or
- R 4d and R 5d can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C 1 -C 4 alkyl, C -C 4 alkoxy, halo, cyano, amino, CF 3 , and N0 2 ;
- U d is selected from: -(CH 2 ) n d -,
- Q d is selected from 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3-phenylene, 1, 4-phenylene, 2 , 3-pyridinylene, 3 , 4-pyridinylene, 2 , 4-pyridinylene, and 3,4- pyridazinylene;
- R 6d is selected from: H, C 1 -C 4 alkyl, and benzyl;
- R 7d and R 8d are independently selected from: H, C -C ⁇ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(C ⁇ -C 6 alkyl)-, and heteroaryl (Co -C ⁇ alkyl)-.
- R l l d ig selected from H, halogen, CF 3 , CN, N0 , hydroxy, NR 2d R 3d , C 1 -C 4 alkyl substituted with 0-1 R 21d , C 1 -C 4 alkoxy substituted with 0-1 R 21d , aryl substituted with 0-1 R 21d , aryl(C ⁇ -C 6 alkyl)- substituted with
- X d is -C(R 12d ) (R 14d )-C(R 12 ) (R 15d )-; or alternatively, W d and X d can be taken together to be
- R l 2 d i s selected from H, halogen, Ci-C ⁇ alkyl, C 2 -C ⁇ alkenyl, C 2 -C ⁇ alkynyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkylalkyl, (C 1 -C 4 alkyl) carbonyl, aryl, and aryl(C ⁇ -C 6 alkyl)-;
- R i3d is selected from H, Ci-C ⁇ alkyl, C 3 -C 7 cycloalkylmethyl, and aryl (Ci-C ⁇ alkyl)-;
- R 14d is selected from:
- Ci-C ⁇ alkylthio(C ⁇ -C ⁇ alkyl) -, aryl(C ⁇ -C ⁇ o alkylthioalkyl) -, aryl (C 1 -C 10 alkoxyalkyl)-, C 1 -C 10 alkyl, C 1 -C 10 alkoxyalkyl, Ci-C ⁇ hydroxyalkyl, c 2 -C ⁇ o alkenyl, C -C ⁇ o alkynyl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl (Ci-C ⁇ alkyl)-, heteroaryl (Ci-C ⁇ alkyl)-, aryl, heteroaryl, C0 2 R 17d , C( 0)R 17d , and CONR 17d R 20d , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstitute
- C 1 -C 10 alkylaminoalkyl, C 1 -C 10 dialkylaminoalkyl, (C 1 -C 10 alkyl) carbonyl, aryl (Ci-C ⁇ alkyl ) carbonyl , C -C 10 alkenyl, C -C 10 alkynyl ,C 3 ⁇ C ⁇ o cycloalkyl, C 3 -C 10 cycloalkylalkyl, aryl (Ci-C ⁇ alkyl)-, heteroaryl (Ci-C ⁇ alkyl)-, aryl, heteroaryl, C0 2 R 17d , C( 0)R 17d , CONR 17d R 20d , S0 2 R 17d , and SO 2 NR 1 d R 2 0d, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R lld ;
- Y d is selected from: -COR 19d , -SO 3 H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , - C0NHS0 R 17d , -CONHS0NHR 1 d , -NHCOCF 3 , - NHCONHS0 2 R 17d , -NHS0 2 R 17d , -OP0 3 H 2 , -OSO3H , -P0 H 2 , - SO3H , -S0 2 NHCOR 17d , -S0 2 NHC0 2 R 17d ,
- R 17d is selected from:
- R 18d i s selected from: -H,
- R 19d is selected from: hydroxy, C ⁇ -C ⁇ o alkyloxy,
- R 20d is selected from: H, C ⁇ -C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C ⁇ cycloalkylalkyl, aryl, aryl (C ⁇ -C ⁇ alkyl)-, and heteroaryl (C ⁇ -C ⁇ alkyl)-.
- R 2 l d i s selected from: COOH and NR 6d 2 ; d m is 0-4 ; d n is 0-4 ; d t is 0-4 ; d P is 0-2 ; d q is 0-2 ; and d r is 0-2 ;
- n and m are chosen such that the value of n plus d d m is greater than one unless U is d d d -(CH 2 ) t Q (CH 2 ) m -;
- Q is a peptide selected from the group:
- R 1 is L-valine, D-valine or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
- R 2 is L-phenylalanine, D-phenylalanine, D-1-naphthylalanine, 2-aminothiazole-4-acetic acid or tyrosine, the tyrosine optionally substituted on the hydroxy group with a bond to L n ;
- R 3 is D-valine
- R 4 is D-tyrosine substituted on the hydroxy group with a bond to L n ;
- R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine;
- At least one Q is a compound of Formula (la) or (lb) ;
- d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
- d' is 1-100
- L n is a linking group having the formula:
- aa is independently at each occurrence an amino acid
- Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 -- 0 cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
- R 11 is independently selected at each occurrence from the group: H, -OPO3H2, alkyl substituted with 0-1
- R 12 is a bond to C ;
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 , S, SH, S(Pg), 0, OH, PR 13 , PR 13 R 14 , P(0)R 15 R 16 , and a bond to L n ;
- E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3
- heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and
- R 13 and R 14 are each independently selected from the group: a bond to L n , hydrogen, C ⁇ -C ⁇ o alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C ⁇ - ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C ⁇ - ⁇ o aryl-C ⁇ - ⁇ o alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C ⁇ - ⁇ o aryl- substituted with 0-3 R 1 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 14 is an electron,
- R 15 and R 16 are each independently selected from the group: a bond to L n , -OH, Ci-Cio alkyl substituted with 0-3 R 17 , Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ 10 alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C ⁇ -xo aryl-C ⁇ _ ⁇ 0 alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C ⁇ -xo aryl- substituted with 0-3 R 17 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17
- R 18 , R 1 a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, C -CQ alkyl, phenyl, benzyl, C1-C6 alkoxy, halide, nitro, cyano, and trifluoromethyl;
- Pg is a thiol protecting group
- R 20 and R 21 taken together with the divalent carbon radical to which they are attached form :
- R 22 and R 23 are independently selected from the group: H, R 24 , C1-C10 alkyl substituted with 0-3 R 24 , C2-C10 alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 24 , and C 3 -- X0 carbocycle substituted with 0-3 R 24 ;
- R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
- a and b indicate the positions of optional double bonds and n is 0 or 1;
- R 25 , R 25a , and R 26 are each independently selected at each occurrence from the group: hydrogen and Ci-Cg alkyl .
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein wherein the radioisotope is 99m Tc or 95 Tc, the radiopharmaceutical further comprises a first ancillary ligand and a second ancillary ligand capable of stabilizing the radiopharmaceutical.
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the radioisotope is "m-c. [18] In another embodiment, the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 17, wherein the radiopharmaceutical is selected from the group:
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the radioisotope is
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein, the radiopharmaceutical is selected from the group:
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the radioisotope is 153 Sm.
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the radioisotope is 177 Lu.
- the present invention provides a therapeutic composition according to Embodiment 22, wherein the radiopharmaceutical is
- the present invention provides a therapeutic composition according to Embodiment 24, wherein, the radiopharmaceutical is selected from the group:
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 29 , wherein the targeting moiety is a indazole and the receptor is o. ⁇ 3 or 0Cv ⁇ 5 • [27]
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 14, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine,
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 14, wherein radiosensitizer agent is selected from the group consiting of 2- (3- nitro-1, 2, 4-triazol-l-yl) -N- (2-methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4-morpholinecarboxamidine, 3- amino-1, 2 , 4-benzotriazine-l, 4-dioxide, N- (2- hydroxyethyl) -2-nitroimidazole-l-acetamide, 1- (2- nitroimidazol-1-yl) -3- (1-piperidinyl) -2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1-aziridino) -2-propanol .
- radiosensitizer agent is selected from the group consiting of 2- (3- nitro-1, 2, 4-triazol-l-yl) -N
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 14, wherein the radioisotope is selected from the group 33 P, 125 I, 186 Re, 188 Re, 153 Sm, 166 Ho , 1 7 Lu, 1 9 Pm, 9 0 ⁇ , 212 Bi# 103 Pd/ 109 Pd/ 159 Gd/ 140 La , 198 AU 199 AU/ 169 ⁇ b 175 ⁇ b; 165 Dy/ 166 Dy/ 67 Cu , 105 Rh, 11:1 -Ag, and 192 Ir, and the linking group is present between the non-peptide targeting moiety and chelator.
- the radioisotope is selected from the group 33 P, 125 I, 186 Re, 188 Re, 153 Sm, 166 Ho , 1 7 Lu, 1 9 Pm, 9 0 ⁇ , 212 Bi# 103 Pd/ 109 Pd/ 159 Gd/ 140 La , 198 AU 199 AU/ 169 ⁇
- the present invention provides a method of treating cancer in a patient comprising: administering to a patient in need thereof a therapeutic radiopharmaceutical comprising: a) a radioisotope; b) a chelator capable of chelating the radioisotope 1; and c) a targeting moiety; wherein the targeting moiety is bound to the chelator through a linking group, and the targeting moiety is a indazole nonpeptide that binds to a receptor that is upregulated during angiogenesis, and the radioisotope is a radioisotope selected from the group: 33 # 1 ⁇ , 186 Re , 188 Re , 153 Sm , 166 H ⁇ / 177 LU/ 149 Pm , 90 ⁇ , 212 Bi# 103 Pd , 109 Pd , 159 Gd , 140 La/ 198 AU/ 199 Au , 169 Yb , 175 ⁇ b , 165 Dy , 166 Dy
- the present invention provides a method according to Embodiment 30, wherein the targeting moiety is an indazole non-peptide and the receptor is ⁇ v ⁇ 3 or ⁇ v ⁇ 5 •
- the present invention provides a method according to Embodiment 30, wherein the therapeutic radiopharmaceutical comprises : a) a radioisotope selected from the group: 33 P, 12 ⁇ I,
- X ld is N, CH, C-W d -X d -Y d , or C-L n ;
- X 2d is N, CH, or C-W d -X d -Y d ;
- X 3d is N, CR lld , or C-W d -X d -Y d ;
- X d is N or CR lld ;
- R ld is selected from: R lde , C ⁇ -C ⁇ alkyl substituted with 0-1 R 15d or 0-1 R 21d , C 3 -C 6 alkenyl substituted with 0-1 R 15d or 0-1 R 21d , C3-C7 cycloalkyl substituted with 0-1 R 15d or 0-1 R 21d , C -C ⁇ cycloalkylalkyl substituted with 0-1 R 15d or 0-1 R 21d , aryl substituted with 0-1 R 15 or 0-2 R lld or 0-1 R2ld and aryl(C ⁇ -C ⁇ alkyl)- substituted with 0-1 R 15d or 0-2 R lld or 0-1 R 21d ; R lde is selected from:
- a ld and B ld are independently -CH 2 - or -N(R 3d )-;
- J d , K d , L d and M d are independently selected from
- R 2d is selected from: H, C ⁇ -C ⁇ alkyl, (C ⁇ -Ce alkyl) carbonyl, (C ⁇ -C ⁇ alkoxy) carbonyl; (C ⁇ -C ⁇ alkyl) aminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 ⁇ C ⁇ cycloalkylalkyl, aryl, heteroaryl (C ⁇ -C ⁇ alkyl ) carbonyl , heteroarylcarbonyl , aryl(C ⁇ -C ⁇ alkyl)-, (C ⁇ -C ⁇ alkyl) carbonyl- , arylcarbonyl, C ⁇ -Ce alkylsulfonyl, arylsulfonyl, aryl(C ⁇ -C ⁇ alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (C ⁇ -C ⁇ alkyl) sulfonyl,
- R 4d and R 5d are independently selected from: H, C ⁇ -C 4 alkoxy, NR 2d R 3d , halogen, N0 , CN, CF 3 , C ⁇ -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C cycloalkylalkyl, aryl, aryl (C ⁇ -C ⁇ alkyl)-, (C ⁇ -C ⁇ alkyl ) carbonyl , (C ⁇ -C ⁇ alkoxy) carbonyl, and arylcarbonyl, or
- R 4d and R 5d can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, halo, cyano, amino, CF 3 , and N0 2 ;
- U d is selected from:
- Q d is selected from 1, 2-cycloalkylene, 1, 2-phenylene, 1, 3 -phenyl ene, 1, 4 -phenyl ene, 2 , 3-pyridinylene,
- R 6d is selected from: H, C ⁇ -C4 alkyl, and benzyl;
- R 7d and R 8d are independently selected from: H, C ⁇ -C ⁇ alkyl, C3-C7 cycloalkyl, C4 ⁇ C ⁇ cycloalkylalkyl, aryl, aryl(C ⁇ -C ⁇ alkyl)-, and heteroaryl (C ⁇ -C ⁇ alkyl)-,.
- R lld i s selected from H, halogen, CF 3 , CN, N0 2 , hydroxy, NR 2d R 3 , C ⁇ -C alkyl substituted with 0-1 R 21d , C ⁇ -C alkoxy substituted with 0-1 R 21d , aryl substituted with 0-1 R 21d , aryl(C ⁇ -C 6 alkyl)- substituted with
- X d is -C(R 12d ) (R 1 d )-C(R 12d ) (R 15d )-; or alternatively, W d and X d can be taken together to be
- R l2d i s selected from H, halogen, C ⁇ -C ⁇ alkyl, C 2 -C ⁇ alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, C 4 -C X0 cycloalkylalkyl, (C ⁇ -C 4 alkyl) carbonyl, aryl, and aryl(C ⁇ -C ⁇ alkyl)-;
- R 13d is selected from H, C ⁇ -C ⁇ alkyl, C 3 -C 7 cycloalkylmethyl, and aryl(C ⁇ -C ⁇ alkyl)-;
- R 14d is selected from:
- R 15d i s selected from:
- C 1 -C 10 alkylaminoalkyl , C 1 -C 10 dialkylaminoalkyl , (C 1 -C 10 alkyl ) carbonyl , aryl (Ci-C ⁇ alkyl) carbonyl, C 1 -C 10 alkenyl, C 1 -C 10 alkynyl ,C 3 -C ⁇ o cycloalkyl, c 3 -C ⁇ o cycloalkylalkyl, aryl (Ci-C ⁇ alkyl)-, heteroaryl (Ci-C ⁇ alkyl)-, aryl, heteroaryl, C0 2 R 17d , C( 0)R 17d , CONR 17d R 20d , S0 2 R 17d , and SO 2 NR 17d R 20d , provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 0-2 R lld
- Y d is selected from: -COR 19d , -SO 3 H, -PO 3 H, tetrazolyl, -CONHNHS0 2 CF 3 , - C0NHS0 2 R 17d , -CONHS0 2 NHR 17d , -NHCOCF 3 , - NHCONHS0 2 R 17d , -NHS0 2 R 17d , -OP0 3 H 2 , -OSO3H , -P ⁇ 3H 2 , SO3H , -S0 2 NHCOR 17 d , -S0 2 NHC0 R 17d ,
- R l7d ig selected from:
- i8d is selected from: -H,
- R l9d is selected from: hydroxy, C 1 -C 10 alkyloxy,
- C 5 _C 10 (5-alkyl-l, 3-dioxa-cyclopenten-2-one- yl)methyloxy
- C 10 -C 14 (5-aryl-l, 3-dioxa- cyclopenten-2-one-yl)methyloxy
- R 20d i s selected from: H, Ci-C ⁇ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl(Ci-Ce alkyl)-, and heteroaryl (Ci-C ⁇ alkyl)-,.
- R 2ld ig selected from: COOH and NR 6d 2 ; d m is 0-4 ; d n is 0-4 ; d t is 0-4 ; d P is 0-2 ; d q is 0-2 ; and d r is 0-2 ;
- t , n , m and q are chosen such that the number of atoms connecting R ld and Y is in the range of 10-14; and d d d
- n and m are chosen such that the value of n plus d d m is greater than one unless U is d d d -(CH 2 ) t Q (CH 2 ) m -;
- Q is a peptide selected from the group:
- R 1 is L-valine, D-valine or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
- R 2 is L-phenylalanine, D-phenylalanine, D-1-naphthylalanine, 2-aminothiazole-4-acetic acid or tyrosine, the tyrosine optionally substituted on the hydroxy group with a bond to L n ;
- R 3 is D-valine
- R 4 is D-tyrosine substituted on the hydroxy group with a bond to L n ;
- R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine ;
- At least one Q is a compound of Formula (la) or (lb) ;
- d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
- d' is 1-100
- L n is a linking group having the formula:
- aa is independently at each occurrence an amino acid
- Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 -- 10 cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
- R 11 is independently selected at each occurrence from the group: H, -OPO3H2, alkyl substituted with 0-1
- R 12 is a bond to C h ;
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 , S, SH, S(Pg), O, OH, PR 13 , PR 13 R 14 , P(0)R 15 R 16 , and a bond to L n ;
- E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 -. 10 cycloalkyl substituted with 0-3
- heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and
- R 13 and R 14 are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 7 , C ⁇ _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-Ci-io alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C ⁇ -io aryl-Ci-io alkyl substituted with 0-3 R 17 , C ⁇ - ⁇ o alkyl-C ⁇ -io aryl- substituted with 0-3 R 17 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 14 is an electron, then
- R 15 and R 16 are each independently selected from the group: a bond to L n , -OH, Ci-Cio alkyl substituted with 0-3 R 17 , Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 - 10 cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, Cg-io aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C ⁇ -io aryl- substituted with 0-3 R 17 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
- R 18 , R 18a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, C1-C6 alkyl, phenyl, benzyl, Ci-C ⁇ alkoxy, halide, nitro, cyano, and trifluoromethyl;
- Pg is a thiol protecting group
- R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
- R 22 and R 23 are independently selected from the group: H, R 24 , Ci-Cio alkyl substituted with 0-3 R 24 , c 2 -c 10 alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 24 , and C 3 -. 10 carbocycle substituted with 0-3 R 24 ;
- R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
- a and b indicate the positions of optional double bonds and n is 0 or 1;
- R 25, R 25a, and R 26 are each independently selected at each occurrence from the group: hydrogen and Ci-C ⁇ alkyl .
- the present invention provides a method according to Embodiment 30, wherein R lde is selected from:
- a ld and B ld are independently -CH 2 - or -N(R 3d )-;
- d d d d J , K , L and M are independently selected from:
- R 2d ig selected from: H, Ci-C ⁇ alkyl, (Ci-C ⁇ alkyl ) carbonyl , (Ci-C ⁇ alkoxy) carbonyl, Ci-C ⁇ alkylaminocarbonyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, heteroaryl (Ci-C ⁇ alkyl) carbonyl, heteroarylcarbonyl, aryl (Ci-C ⁇ alkyl)-, (Ci-C ⁇ alkyl ) carbonyl , arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(C ⁇ -C ⁇ alkyl) sulfonyl, heteroarylsulfonyl, heteroaryl (Ci-C ⁇ alkyl) sulfonyl, aryloxycarbon
- R 3d is selected from: H, Ci-Cs alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-C ⁇ alkyl)-, and heteroaryl (Ci-Ce alkyl)-,.
- R 4 and R 5d are independently selected from: H, C 1 -C 4 alkoxy, NR 2d R 3d , halogen, N0 2 , CN, CF 3 , C ⁇ -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 7 cycloalkyl, C 4 -C1 1 cycloalkylalkyl, aryl, aryl (Ci-C ⁇ alkyl)-, C -C 7 alkylcarbonyl, and arylcarbonyl;
- R d and R 5d can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from: C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, cyano, amino, CF 3 , or N0 2 ; d U is selected from: d -(CH 2 ) n -,
- d Q is selected from 1, 2-phenylene, 1, 3 -phenylene, 2,3- pyridinylene, 3 , 4-pyridinylene, and 2,4- pyridinylene;
- R 6d is selected from: H, C 1 -C 4 alkyl, and benzyl;
- R 7d and R 8d are independently selected from: H, Ci-C ⁇ alkyl, C 3 -C 7 cycloalkyl, C 4 -C 11 cycloalkylalkyl, aryl, aryl (Ci-Cg alkyl)-, and heteroaryl (C ⁇ -C ⁇ alkyl)-,-
- X is -C(R 12d ) (R 1 d )-C(R 12d ) (R 15d )-;
- R 12d is H or C ⁇ -C 6 alkyl
- d Y is selected from:
- d is selected from 1, 2, 3, 4, and 5;
- aa is independently at each occurrence an amino acid
- Z is selected from the group: aryl substituted with 0-1 R 10 , C 3 -- 10 cycloalkyl substituted with 0-1 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 10 ;
- k is 0 or 1; s is selected from 0, 1, 2, 3, 4, and 5; s' is selected from 0, 1, 2, 3, 4, and 5; s" is selected from 0, 1, 2, 3, 4, and 5; t is selected from 0, 1, 2, 3, 4, and 5;
- a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 S ⁇ SH s(Pg), OH, and a bond to L n ;
- E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-CJo alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 -- 10 cycloalkyl substituted with 0-3
- R 17 and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
- R 13 and R 14 are each independently selected from the group: a bond to L n , hydrogen, C1-C10 alkyl substituted with 0-3 R 17 , aryl substituted with 0-3
- R 17 a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 14 is an electron, then the other is also an electron;
- R 18 , R 18a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, and Ci-Ce alkyl;
- R 20 and R 21 are independently selected from the group:
- R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
- R 22 and R 23 are independently selected from the group: H, and R 24 ;
- R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
- R 25 is independently selected at each occurrence from the group: H and C1-C3 alkyl.
- the present invention provides a method according to Embodiment 30, wherein the therapeutic radiopharmaceutical is selected from the group consisting of:
- TPTS tripeptide
- the present invention provides a method according to Embodiment 30 wherein administering the therapeutic radiopharmaceutical and agent is concurrent.
- the present invention provides a method according to Embodiment 30 wherein administering the therapeutic radiopharmaceutical and agent is sequential .
- the present invention provides a method according to Embodiment 30 wherein the cancer is selected from the group consisting of carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, and neuroblastomas .
- the cancer is selected from the group consisting of carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, me
- the present invention provides a method according to Embodiment 30 wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, is
- the present invention provides a method according to Embodiment 30 wherein the radiosensitizer agent is selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l,2, 4-benzotriazine- 1 , 4-dioxide, N- (2-hydroxyethyl) -2-nitroimidazole-l- acetamide, 1- (2-nitroimidazol-l-yl) -3- (1-piperidinyl) - 2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1- aziridino) -2-propanol .
- the radiosensitizer agent is selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N
- the present invention provides a method according to Embodiment 30 wherein the anti-cancer agent is a anti-cancer agent agent.
- the present invention provides a method of treating cancer according to Embodiment 30, wherein the administration is by injection or infusion.
- the present invention provides a method of Embodiment 30, further comprising treating the cancer by brachytherapy, external beam radiation, laser therapy or surgical removal.
- the present invention provides a kit comprising packaging material, and a therapeutic radiopharmaceutical composition of Embodiment 15, contained within said packaging material, wherein the packaging material comprises a label or package insert which indicates that said therapeutic radiopharmaceutical composition can be used for treating cancer.
- the present invention provides a therapeutic radiopharmaceutical composition of Embodiment 15, further comprising a photosensitizing agent .
- the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 44, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; porphyins ; chlorins;, phthalocyanines ; napthalocyanines ; coumarins, psoralens, 1, 3 , 4, 6-tetramethoxyhelianthrone; 10, 13- dimethyl-l, 3 , 4 , 6-tetrahydroxyhelianthrone; 10, 13- di (methoxycarbonyl) -1,3,4, 6-tetramethoxyhelianthrone;
- the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; porphyins ; chlorins;, phthalocyanines ; nap
- the present invention provides a kit according to Embodiment 43 , further comprising a photosensitizing agent.
- the present invention provides a kit according to Embodiment 46, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; porphyins; chlorins;, phthalocyanines; napthalocyanines; coumarins, psoralens, 1,3,4,6- tetramethoxyhelianthrone; 10 , 13-dimethyl-l ,3,4,6- tetrahydroxyhelianthrone; 10 , 13-di (methoxycarbonyl) - 1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino- 3 , 4-dimethoxy-helianthrone; 1, 6-di-N-butylamino-3 , 4- dimethoxy-10 , 13-dimethyl-helianthrone; 1, 6-di- (
- the present invention provides a method of treating cancer according to Embodiment 30, further comprising treating the patient with photodynamic therapy.
- the present invention provides a method of treating cancer according to Embodiment 48, wherein the photodynamic therapy comprises : a) administering a therapeutic radiopharmaceutical of the present invention and a photosensitive agent (photoreactive agent) to a patient, said photosensitive agent having a characteristic light absorption waveband and being preferentially absorbed by abnormal tissue; b) providing an imaging device that is integral with a plurality of light sources and produces a signal used for imaging abnormal tissue at the internal treatment site, said light sources emitting light in a waveband corresponding to the characteristic light absorption waveband of the photosensitive agent, said waveband including wavelengths sufficiently long to penetrate through a dermal layer of the patient to the internal treatment site;
- the present invention provides a method of treating cancer according to Embodiment 55, wherein the photosensitive agent (photoreactive agent) is specifically targeted at the targeted tissue by including a binding agent that selectively links the photosensitive agent to the targeted tissue.
- the photosensitive agent photoreactive agent
- the present invention provides a method of treating cancer according to Embodiment 49, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole- based photosensitizers; porphyins; chlorins;, phthalocyanines ; napthalocyanines; cou arins, psoralens, 1,3,4, 6-tetramethoxyhelianthrone; 10, 13 -dimethyl- 1, 3 , 4, 6-tetrahydroxyhelianthrone; 10,13- di (methoxycarbonyl) -1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino-3 , 4-dimethoxy-helianthrone; 1, 6-di- N-butylamino-3 , 4-dimethoxy-10 , 13 -dimethyl-helianthrone; 1, 6-di- (N-
- Diagnostic kits of the present invention comprise one or more vials containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of a reagent of the present invention, and optionally other components such as one or two ancillary ligands, reducing agents, transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats .
- the inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practicing end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical.
- the inclusion of one or two ancillary ligands is required for diagnostic kits comprising reagent comprising a hydrazine or hydrazone bonding moiety.
- the one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.
- Diagnostic kits of the present invention comprise one or more vials containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of a reagent of the present invention, and optionally other components such as one or two ancillary ligands, reducing agents, transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats .
- the inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practicing end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical.
- the inclusion of one or two ancillary ligands is required for diagnostic kits comprising reagent comprising a hydrazine or hydrazone bonding moiety.
- the one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.
- Another aspect of the present invention contemplates a method of imaging cancer in a patient involving: (1) synthesizing a diagnostic radiopharmaceutical of the present invention, using a reagent of the present invention, capable of localizing in tumors; (2) administering said radiopharmaceutical to a patient by injection or infusion; (3) imaging the patient using planar or SPECT gamma scintigraphy, or positron emission tomography.
- Another aspect of the present invention contemplates a method of imaging cancer in a patient involving: (1) administering a paramagnetic metallopharmaceutical of the present invention capable of localizing in tumors to a patient by injection or infusion; and (2) imaging the patient using magnetic resonance imaging.
- Another aspect of the present invention contemplates a method of imaging cancer in a patient involving: (1) administering a X-ray contrast agent of the present invention capable of localizing in tumors to a patient by injection or infusion; and (2) imaging the patient using X-ray computed tomography.
- Another aspect of the present invention contemplates a method of imaging cancer in a patient involving: (1) administering a ultrasound contrast agent of the present invention capable of localizing in tumors to a patient by injection or infusion; and (2) imaging the patient using sonography.
- Another aspect of the present invention contemplates a method of treating cancer in a patient involving: (1) administering a therapeutic radiopharmaceutical of the present invention capable of localizing in tumors to a patient by injection or infusion.
- Another aspect of the present invention contemplates the combination of anti-cancer agents and angiogenesis-targeted therapeutic radiopharmaceuticals of the invention, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
- Another aspect of the present invention contemplates the compounds of the present invention (i.e.
- a compound comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a indazole nonpeptide, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator) which is administered in combination therapy, with one or more anti-cancer agent (s) selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine,
- This combination therapy may further, optionally, include a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, to enhance the radiotherapeutic effect together with the anti-cancer agent, said radiosensitizer agent being selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine- 1, 4-dioxide, N- (2-hydroxyethyl) -2-nitroimidazole-l- acetamide, 1- (2-nitroimidazol-1-yl) -3- ( 1-piperidinyl ) - 2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1- aziridino) -2-propanol .
- a radiosensitizer agent being
- radiosensitizer agents are provided in the following: Rowinsky-EK, Oncology-Huntingt . , 1999 Oct; 13(10 Suppl 5): 61-70; Chen-AY et al . , Oncology-Huntingt. 1999 Oct; 13(10 Suppl 5): 39-46; Choy-H, Oncology-Huntingt. 1999 Oct; 13(10 Suppl 5): 23-38; and Herscher-LL et al, Oncology-Huntingt. 1999 Oct; 13(10 Suppl 5): 11-22, which are incorporated herein by reference.
- kits having a plurality of active ingredients (with or without carrier) which, together, may be effectively utilized for carrying out the novel combination therapies of the invention.
- the present invention provides a method for treating cancer in a patient in need of such treatment, said method including the steps of administering a therapeutically effective amount of a compound of the present invention and administering a therapeutically effective amount of at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent.
- a therapeutically effective amount of a compound of the present invention and administering a therapeutically effective amount of at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent.
- any variable occurs more than one time in any substituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence.
- a group is shown to be substituted with 0-2 R 52 , then said group may optionally be substituted with up to two R 52 , and R 52 at each occurrence is selected independently from the defined list of possible R 52 .
- R 52 at each occurrence is selected independently from the defined list of possible R 52 .
- each of the two R 53 substituents on N is independently selected from the defined list of possible R 53 .
- Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds .
- nonpeptide means preferably less than three amide bonds in the backbone core of the targeting moiety or preferably less than three amino acids or amino acid mimetics in the targeting moiety.
- metallopharmaceutical means a pharmaceutical comprising a metal. The metal is the cause of the imageable signal in diagnostic applications and the source of the cytotoxic radiation in radiotherapeutic applications. Radiopharmaceuticals are metallopharmaceuticals in which the metal is a radioisotope.
- reagent is meant a compound of this invention capable of direct transformation into a metallopharmaceutical of this invention. Reagents may be utilized directly for the preparation of the metallopharmaceuticals of this invention or may be a component in a kit of this invention.
- binding agent means a metallopharmaceutical of this invention having affinity for and capable of binding to the vitronectin receptor.
- the binding agents of this invention have Ki ⁇ lOOOnM.
- stable compound or “stable structure” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious pharmaceutical agent .
- substituted means that one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's or group's normal valency is not exceeded, and that the substitution results in a stable compound.
- 2 hydrogens on the atom are replaced.
- bond means either a single or double bond.
- salt is used as defined in the CRC Handbook of Chemistry and Physics, 65th Edition, CRC Press, Boca Raton, Fla, 1984, as any substance which yields ions, other than hydrogen or hydroxyl ions.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds modified by making acid or base salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- prodrugs as used herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- prodrug means compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention.
- alkanoyl such as acetyl, propionyl, butyryl, and the like
- unsubstituted and substituted aroyl such as benzoyl and substituted benzoyl
- alkoxycarbonyl such as ethoxycarbonyl
- trialkylsilyl such as trimethyl- and triethysilyl
- monoesters formed with dicarboxylic acids such as succinyl
- the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.
- prodrugs A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed. , Elsevier, 1985; Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-396, 1985; A Textbook of Drug Design and Development,
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
- inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
- organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, tartaric
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
- Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl; "cycloalkyl” or “carbocycle” is intended to include saturated and partially unsaturated ring groups, including mono-, bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and adamantyl; "bicycloalkyl” or "bicyclic” is intended to include saturated bicycl
- alkene or “alkenyl” is intended to include hydrocarbon chains having the specified number of carbon atoms of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
- alkyne or “alkynyl” is intended to include hydrocarbon chains having the specified number of carbon atoms of either a straight or branched configuration and one or more unsaturated carbon-carbon triple bonds which may occur in any stable point along the chain, such as propargyl, and the like.
- aryl or “aromatic residue” is intended to mean phenyl or naphthyl, which when substituted, the substitution can be at any position.
- heterocycle or
- heterocyclic system is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
- the nitrogen and sulfur heteroatoms may optionally be oxidized.
- the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
- heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1.
- aromatic heterocyclic system is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
- heterocycles include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H,6H-l,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1, 2 , 5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinol,
- oxazolyl oxazolidinylperimidinyl, phenanthridinyl , phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl
- Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles .
- alkaryl means an aryl group bearing an alkyl group of 1-10 carbon atoms
- aralkyl means an alkyl group of 1-10 carbon atoms bearing an aryl group
- arylalkaryl means an aryl group bearing an alkyl group of 1-10 carbon atoms bearing an aryl group
- heterocycloalkyl means an alkyl group of 1-10 carbon atoms bearing a heterocycle .
- a "polyalkylene glycol” is a polyethylene glycol, polypropylene glycol or polybutylene glycol having a molecular weight of less than about 5000, terminating in either a hydroxy or alkyl ether moiety.
- a “carbohydrate” is a polyhydroxy aldehyde, ketone, alcohol or acid, or derivatives thereof, including polymers thereof having polymeric linkages of the acetal type.
- a "cyclodextrin” is a cyclic oligosaccharide.
- cyclodextrins include, but are not limited to, -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, carboxymethyl- ⁇ -cyclodextrin, dihydroxypropyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, 2,6 di-O-methyl- ⁇ -cyclodextrin, sulfated- ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, dihydroxypropyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, and sulfated ⁇ -cyclodextrin.
- polycarboxyalkyl means an alkyl group having between two and about 100 carbon atoms and a plurality of carboxyl substituents; and the term “polyazaalkyl” means a linear or branched alkyl group having between two and about 100 carbon atoms, interrupted by or substituted with a plurality of amine groups .
- a "reducing agent” is a compound that reacts with a radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transferring electron (s) to the radionuclide, thereby making it more reactive.
- Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et . al . , PCT Application 94/22496, which is incorporated herein by reference .
- a "transfer ligand” is a ligand that forms an intermediate complex with a metal ion that is stable enough to prevent unwanted side-reactions but labile enough to be converted to a metallopharmaceutical.
- Transfer ligands useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of diagnostic radiopharmaceuticals include but are not limited to gluconate, glucoheptonate, mannitol, glucarate,
- transfer ligands are comprised of oxygen or nitrogen donor atoms .
- donor atom refers to the atom directly attached to a metal by a chemical bond.
- Radionuclide coordination sphere is composed of one or more chelators or bonding units from one or more reagents and one or more ancillary or co-ligands, provided that there are a total of two types of ligands, chelators or bonding units.
- a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two of the same ancillary or co-ligands and a radiopharmaceutical comprised of two chelators or bonding units from one or two reagents and one ancillary or co-ligand are both considered to be comprised of binary ligand systems.
- the radionuclide coordination sphere is composed of one or more chelators or bonding units from one or more reagents and one or more of two different types of ancillary or co-ligands, provided that there are a total of three types of ligands, chelators or bonding units.
- a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two different ancillary or co-ligands is considered to be comprised of a ternary ligand system.
- Ancillary or co-ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals are comprised of one or more oxygen, nitrogen, carbon, sulfur, phosphorus, arsenic, selenium, and tellurium donor atoms.
- a ligand can be a transfer ligand in the synthesis of a radiopharmaceutical and also serve as an ancillary or co-ligand in another radiopharmaceutical.
- a ligand is termed a transfer or ancillary or co-ligand depends on whether the ligand remains in the radionuclide coordination sphere in the radiopharmaceutical, which is determined by the coordination chemistry of the radionuclide and the chelator or bonding unit of the reagent or reagents.
- a "chelator” or “bonding unit” is the moiety or group on a reagent that binds to a metal ion through the formation of chemical bonds with one or more donor atoms .
- binding site means the site in vivo or in vitro that binds a biologically active molecule.
- a “diagnostic kit” or “kit” comprises a collection of components, termed the formulation, in one or more vials which are used by the practicing end user in a clinical or pharmacy setting to synthesize diagnostic radiopharmaceuticals.
- the kit provides all the requisite components to synthesize and use the diagnostic radiopharmaceutical except those that are commonly available to the practicing end user, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical, if required, equipment necessary for administering the radiopharmaceutical to the patient such as syringes and shielding, and imaging equipment.
- Radiopharmaceuticals, X-ray contrast agent pharmaceuticals, ultrasound contrast agent pharmaceuticals and metallopharmaceuticals for magnetic resonance imaging contrast are provided to the end user in their final form in a formulation contained typically in one vial, as either a lyophilized solid or an aqueous solution.
- the end user reconstitutes the lyophilized with water or saline and withdraws the patient dose or just withdraws the dose from the aqueous solution formulation as provided.
- a "lyophilization aid" is a component that has favorable physical properties for lyophilization, such as the glass transition temperature, and is added to the formulation to improve the physical properties of the combination of all the components of the formulation for lyophilization .
- a “stabilization aid” is a component that is added to the metallopharmaceutical or to the diagnostic kit either to stabilize the metallopharmaceutical or to prolong the shelf-life of the kit before it must be used.
- Stabilization aids can be antioxidants , reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the metallopharmaceutical.
- a “solubilization aid” is a component that improves the solubility of one or more other components in the medium required for the formulation.
- a "bacteriostat” is a component that inhibits the growth of bacteria in a formulation either during its storage before use of after a diagnostic kit is used to synthesize a radiopharmaceutical.
- bubbles refers to vesicles which are generally characterized by the presence of one or more membranes or walls surrounding an internal void that is filled with a gas or precursor thereto.
- Exemplary bubbles include, for example, liposomes, micelles and the like.
- lipid refers to a synthetic or naturally-occurring amphipathic compound which comprises a hydrophilic component and a hydrophobic component. Lipids include, for example, fatty acids, neutral fats, phosphatides, glycolipids, aliphatic alchols and waxes, terpenes and steroids.
- lipid composition refers to a composition which comprises a lipid compound.
- lipid compositions include suspensions, emulsions and vesicular compositions.
- lipid formulation refers to a composition which comprises a lipid compound and a bioactive agent.
- vesicle refers to a spherical entity which is characterized by the presence of an internal void.
- Preferred vesicles are formulated from lipids, including the various lipids described herein.
- the lipids may be in the form of a monolayer or bilayer, and the mono- or bilayer lipids may be used to form one of more mono- or bilayers. In the case of more than one mono- or bilayer, the mono- or bilayers are generally concentric.
- the lipid vesicles described herein include such entities commonly referred to as liposomes, micelles, bubbles, microbubbles, microspheres and the like.
- the lipids may be used to form a unilamellar vesicle (comprised of one monolayer or bilayer) , an oligolamellar vesicle (comprised of about two or about three monolayers or bilayers) or a multilamellar vesicle (comprised of more than about three monolayers or bilayers) .
- the internal void of the vesicles may be filled with a liquid, including, for example, an aqueous liquid, a gas, a gaseous precursor, and/or a solid or solute material, including, for example, a bioactive agent, as desired.
- vesicular composition refers to a composition which is formulate from lipids and which comprises vesicles.
- vesicle formulation refers to a composition which comprises vesicles and a bioactive agent.
- lipomes refers to a generally spherical cluster or aggregate of amphipathic compounds, including lipid compounds, typically in the form of one or more concentric layers, for example, bilayers . They may also be referred to herein as lipid vesicles .
- Angiogenesis is the process of formation of new capillary blood vessels from existing vasculature. It is an important component of a variety of physiological processes including ovulation, embryonic development, wound repair, and collateral vascular generation in the myocardium. It is also central to a number of pathological conditions such as tumor growth and metastasis, diabetic retinopathy, and macular degeneration.
- the process begins with the activation of existing vascular endothelial cells in response to a variety of cytokines and growth factors .
- the activated endothelial cells secrete enzymes that degrade the basement membrane of the vessels .
- the endothelial cells then proliferate and migrate into the extracellular matrix first forming tubules and subsequently new blood vessels .
- endothelial cell proliferation is a very slow process, but it increases for a short period of time during embryogenesis, ovulation and wound healing. This temporary increase in cell turnover is governed by a combination of a number of growth stimulatory factors and growth suppressing factors. In pathological angiogenesis, this normal balance is disrupted resulting in continued increased endothelial cell proliferation.
- proangiogenic factors include basic fibroblast growth factor (bFGF) , angiogenin, TGF- alpha, TGF-beta, and vascular endothelium growth factor (VEGF)
- interferon-alpha, interferon-beta and thrombospondin are examples of angiogenesis suppressors.
- Angiogenic factors interact with endothelial cell surface receptors such as the receptor tyrosine kinases EGFR, FGFR, PDGFR, Flk-1/KDR, Flt-1, Tek, Tie, neuropilin-1, endoglin, endosialin, and Axl .
- the receptors Flk-1/KDR, neuropilin-1, and Flt-1 recognize VEGF and these interactions play key roles in VEGF- induced angiogenesis.
- the Tie subfamily of receptor tyrosine kinases are also expressed prominently during blood vessel formation. The proliferation and migration of endothelial cells in the extracellular matrix is mediated by interaction with a variety of cell adhesion molecules .
- Integrins are a diverse family of heterodimeric cell surface receptors by which endothelial cells attach to the extracellular matrix, each other and other cells.
- Angiogenesis induced by bFGF or TNF-alpha depend on the agency of the integrin avb3
- angiogenesis induced by VEGF depends on the integrin avb5 (Cheresh et. al . , Science, 1995, 270, 1500-2).
- Induction of expression of the integrins albl and a2bl on the endothelial cell surface is another important mechanism by which VEGF promotes angiogenesis (Senger, et . al . , Proc. Natl. Acad, Sci USA, 1997, 94, 13612-7).
- the pharmaceuticals of the present invention are comprised of a non-peptide targeting moiety for the vitronectin receptor that is expressed or upregulated in angiogenic tumor vasculature.
- the ultrasound contrast agents of the present invention comprise a plurality of vitronectin receptor targeting moieties attached to or incorporated into a microbubble of a biocompatible gas, a liquid carrier, and a surfactant microsphere, further comprising an optional linking moiety, L n , between the targeting moieties and the microbubble.
- liquid carrier means aqueous solution
- surfactant means any amphiphilic material which produces a reduction in interfacial tension in a solution.
- surfactant microsphere includes nanospheres, liposomes, vesicles and the like.
- the biocompatible gas can be air, or a fluorocarbon, such as a C 3 -C 5 perfluoroalkane, which provides the difference in echogenicity and thus the contrast in ultrasound imaging.
- the gas is encapsulated or contained in the microsphere to which is attached the biodirecting group, optionally via a linking group.
- the attachment can be covalent, ionic or by van der Waals forces .
- Specific examples of such contrast agents include lipid encapsulated perfluorocarbons with a plurality of tumor neovasculature receptor binding peptides, polypeptides or peptidomimetics .
- X-ray contrast agents of the present invention are comprised of one or more vitronectin receptor targeting moieties attached to one or more X-ray absorbing or "heavy" atoms of atomic number 20 or greater, further comprising an optional linking moiety, L n , between the targeting moieties and the X-ray absorbing atoms.
- the frequently used heavy atom in X-ray contrast agents is iodine.
- X-ray contrast agents comprised of metal chelates (Wallace, R. , U.S. 5,417,959) and polychelates comprised of a plurality of metal ions (Love, D., U.S. 5,679,810) have been disclosed. More recently, multinuclear cluster complexes have been disclosed as X-ray contrast agents (U.S. 5,804,161, PCT WO91/14460, and PCT WO 92/17215).
- MRI contrast agents of the present invention are comprised of one or more vitronectin receptor targeting moieties attached to one or more paramagnetic metal ions, further comprising an optional linking moiety, L n , between the targeting moieties and the paramagnetic metal ions .
- the paramagnetic metal ions are present in the form of metal complexes or metal oxide particles.
- U.S. 5,412,148, and 5,760,191 describe examples of chelators for paramagnetic metal ions for use in MRI contrast agents.
- U.S. 5,801,228, U.S. 5,567,411, and U.S. 5,281,704 describe examples of polychelants useful for complexing more than one paramagnetic metal ion for use in MRI contrast agents.
- U.S. 5,520,904 describes particulate compositions comprised of paramagnetic metal ions for use as MRI contrast agents.
- Administration of a compound of the present invention in combination with such additional therapeutic agents may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each.
- a lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
- the combination of a compound of the present invention with such additional therapeutic agents is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984) , occurs when the therapeutic effect of the compound and agent when administered in combination is greater than the additive effect of the either the compound or agent when administered alone.
- synergistic effect is most clearly demonstrated at levels that are (therapeutically) sub-optimal for either the compound of the present invention, an anti-cancer agent or a radiosensitizer agent alone, but which are highly efficacious in combination.
- Synergy can be in terms of improved tumor response without substantial increases in toxicity over individual treatments alone, or some other beneficial effect of the combination compared with the individual component .
- the compounds of the present invention, and an anti-cancer agent or a radiosensitizer agent, utilized in combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times e.g., sequentially, such that a combined effect is achieved.
- kits or single packages combining two or more active ingredients useful in treating cancer.
- a kit may provide (alone or in combination with a pharmaceutically acceptable diluent or carrier) , the compound of the present invention and additionally at least one agent selected from the group consisting of a anti-cancer agent and a radiosensitizer agent (alone or in combination with diluent or carrier) .
- the pharmaceuticals of the present invention have the formulae, (Q) d -L n - (C h -X) , (Q) a-Ln" (Ch-X 1 ) d' , (Q)d ⁇ L n - (X 2 )d " , and (Q) a-Ln- (X 3 ) , wherein Q represents a non-peptide that binds to a receptor expressed in angiogenic tumor vasculature, d is 1-10, L n represents an optional linking group, C h represents a metal chelator or bonding moiety, X represents a radioisotope, X 1 represents paramagnetic metal ion, X 2 represents a paramagnetic metal ion or heavy atom containing insoluble solid particle, d" is 1-100, and X 3 represents a surfactant microsphere of an echogenic gas.
- Q represents a non-peptide that binds to a receptor expressed in angiogenic tumor vas
- the pharmaceuticals of the present invention can be synthesized by several approaches.
- One approach involves the synthesis of the targeting non-peptide moiety, Q, and direct attachment of one or more moieties, Q, to one or more metal chelators or bonding moieties, C h , or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
- Another approach involves the attachment of one or more moieties, Q, to the linking group, L n , which is then attached to one or more metal chelators or bonding moieties, C h , or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
- Another approach involves the synthesis of a non-peptide, Q, bearing a fragment of the linking group, L n , one or more of which are then attached to the remainder of the linking group and then to one or more metal chelators or bonding moieties, C h , or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
- the non-peptide vitronectin binding moieties, Q can be synthesized using standard synthetic methods known to those skilled in the art. Preferred methods include but are not limited to those methods described below.
- the attachment of linking groups, L n , to the non- peptides, Q; chelators or bonding units, C h , to the non- peptides, , Q, or to the linking groups, L n ; and non- peptides, bearing a fragment of the linking group to the remainder of the linking group, in combination forming the moiety, (QJ a- rw and then to the moiety C h ; can all be performed by standard techniques.
- the targeting moiety Q or the combination (Q) d L n is attached to a coupling group that react with a constituent of the surface of the solid particle.
- the coupling groups can be any of a number of silanes which react with surface hydroxyl groups on the solid particle surface, as described in co-pending United States Patent Application Serial No. 09/356,178, and can also include polyphosphonates, polycarboxylates, polyphosphates or mixtures thereof which couple with the surface of the solid particles, as described in U.S. 5,520,904.
- reaction schemes can be used to attach the non-peptides, Q to the surfactant microsphere, X 3 . These are illustrated in following reaction schemes where Sf represents a surfactant moiety that forms the surfactant microsphere.
- Y is a leaving group or active ester
- the linking group L n can serve several roles. First it provides a spacing group between the metal chelator or bonding moiety, C h , the paramagnetic metal ion or heavy atom containing solid particle, X 2 , and the surfactant microsphere, X 3 , and the one or more of the non-peptides , Q, so as to minimize the possibility that the moieties C h .-X, C h - 1 , X 2 , and X 3 , will interfere with the interaction of the recognition sequences of Q with angiogenic tumor vasculature receptors.
- a linking group also provides • a means of independently attaching multiple non-peptides, Q, to one group that is attached to C h -X, Ch-X 1 , X 2 , or X 3 .
- the linking group also provides a means of incorporating a pharmacokinetic modifier into the pharmaceuticals of the present invention.
- the pharmacokinetic modifier serves to direct the biodistibution of the injected pharmaceutical other than by the interaction of the targeting moieties, Q, with the vitronectin receptors expressed in the tumor neovasculature.
- a wide variety of functional groups can serve as pharmacokinetic modifiers, including, but not limited to, carbohydrates, polyalkylene glycols, peptides or other polyamino acids, and cyclodextrins .
- the modifiers can be used to enhance or decrease hydrophilicity and to enhance or decrease the rate of blood clearance.
- the modifiers can also be used to direct the route of elimination of the pharmaceuticals.
- Preferred pharmacokinetic modifiers are those that result in moderate to fast blood clearance and enhanced renal excretion.
- the metal chelator or bonding moiety, C is selected to form stable complexes with the metal ion chosen for the particular application.
- Chelators or bonding moieties for diagnostic radiopharmaceuticals are selected to form stable complexes with the radioisotopes that have imageable gamma ray or positron emissions, such as "m c ⁇ 95 Tc, mm, 62 Cu, 60 Cu, 64 CU 67 Ga , 68 Ga , 86 Y.
- Chelators for technetium, copper and gallium isotopes are selected from diaminedithiols, monoamine-monoamidedithiols, triamide-monothiols, monoamine-diamide-monothiols, diaminedioximes, and hydrazines .
- the chelators are generally tetradentate with donor atoms selected from nitrogen, oxygen and sulfur.
- Preferred reagents are comprised of chelators having amine nitrogen and thiol sulfur donor atoms and hydrazine bonding units.
- the thiol sulfur atoms and the hydrazines may bear a protecting group which can be displaced either prior to using the reagent to synthesize a radiopharmaceutical or preferably in situ during the synthesis of the radiopharmaceutical.
- Exemplary thiol protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis” John Wiley & Sons, New York (1991), the disclosure of which is hereby incorporated by reference. Any thiol protecting group known in the art can be used. Examples of thiol protecting groups include, but are not limited to, the following: acetamidomethy1, benzamidomethyl, 1-ethoxyethyl, benzoyl, and triphenylmethyl .
- Exemplary protecting groups for hydrazine bonding units are hydrazones which can be aldehyde or ketone hydrazones having substituents selected from hydrogen, alkyl, aryl and heterocycle. Particularly preferred hydrazones are described in co-pending U.S.S.N. 08/476,296 the disclosure of which is herein incorporated by reference in its entirety.
- the hydrazine bonding unit when bound to a metal radionuclide is termed a hydrazido, or diazenido group and serves as the point of attachment of the radionuclide to the remainder of the radiopharmaceutical.
- a diazenido group can be either terminal (only one atom of the group is bound to the radionuclide) or chelating. In order to have a chelating diazenido group at least one other atom of the group must also be bound to the radionuclide.
- the atoms bound to the metal are termed donor atoms .
- Chelators for 11:L In and 86 Y are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1, 4, 7 , 10- tetraazazcyclododecane-l-acetic-4 , 7 , 10- tris (methylacetic) acid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl- 6-methyl-DTPA, and 6, 6" -bis [N,N,N" ,N"- tetra (carboxymethyl) aminomethyl) -4 ' - (3-amino-4- methoxyphenyl ) -2 , 2 ' : 6 ' , 2 " -terpyridine .
- the coordination sphere of metal ion includes all the ligands or groups bound to the metal.
- a transition metal radionuclide to be stable it typically has a coordination number (number of donor atoms) comprised of an integer greater than or equal to 4 and less than or equal to 8; that is there are 4 to 8 atoms bound to the metal and it is said to have a complete coordination sphere.
- the requisite coordination number for a stable radionuclide complex is determined by the identity of the radionuclide, its oxidation state, and the type of donor atoms.
- the coordination sphere is completed by donor atoms from other ligands, termed ancillary or co-ligands, which can also be either terminal or chelating.
- a large number of ligands can serve as ancillary or co-ligands, the choice of which is determined by a variety of considerations such as the ease of synthesis of the radiopharmaceutical, the chemical and physical properties of the ancillary ligand, the rate of formation, the yield, and the number of isomeric forms of the resulting radiopharmaceuticals, the ability to administer said ancillary or co-ligand to a patient without adverse physiological consequences to said patient, and the compatibility of the ligand in a lyophilized kit formulation.
- the charge and lipophilicity of the ancillary ligand will effect the charge and lipophilicity of the radiopharmaceuticals.
- Preferred technetium radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and an ancillary ligand, ⁇ i, or a bonding unit and two types of ancillary A ⁇ i and AL 2 , or a tetradentate chelator comprised of two nitrogen and two sulfur atoms.
- Ancillary ligands A L are comprised of two or more hard donor atoms such as oxygen and amine nitrogen (sp 3 hybridized) .
- the donor atoms occupy at least two of the sites in the coordination sphere of the radionuclide metal; the ancillary ligand A ⁇ _, ⁇ serves as one of the three ligands in the ternary ligand system.
- ancillary ligands A L ⁇ include but are not limited to dioxygen ligands and functionalized aminocarboxylates . A large number of such ligands are available from commercial sources.
- Ancillary dioxygen ligands include ligands that coordinate to the metal ion through at least two oxygen donor atoms. Examples include but are not limited to: glucoheptonate, gluconate, 2-hydroxyisobutyrate, lactate, tartrate, mannitol, glucarate, altol, Kojic acid, 2 , 2-bis (hydroxymethyl) propionic acid, 4, 5-dihydroxy-l, 3-benzene disulfonate, or substituted or unsubstituted 1,2 or 3,4 hydroxypyridinones . (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.)
- Functionalized aminocarboxylates include ligands that have a combination of amine nitrogen and oxygen donor atoms. Examples include but are not limited to: iminodiacetic acid, 2 , 3-diaminopropionic acid, nitrilotriacetic acid, N,N' -ethylenediamine diacetic acid, N,N,N' -ethylenediamine triacetic acid, hydroxyethylethylenediamine triacetic acid, and N,N' -ethylenediamine bis-hydroxyphenylglycine . (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands .
- a series of functionalized aminocarboxylates are disclosed by Bridger et. al . in U.S. Patent 5,350,837, herein incorporated by reference, that result in improved rates of formation of technetium labeled hydrazino modified proteins. We have determined that certain of these aminocarboxylates result in improved yields of the radiopharmaceuticals of the present invention.
- the preferred ancillary ligands A I functionalized aminocarboxylates that are derivatives of glycine; the most preferred is tricine (tris (hydroxymethyl)methylglycine) .
- the most preferred technetium radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and two types of ancillary designated AL and AL 2 , or a diaminedithiol chelator.
- the second type of ancillary ligands A are comprised of one or more soft donor atoms selected from the group: phosphine phosphorus, arsine arsenic, imine nitrogen (sp 2 hybridized) , sulfur (sp 2 hybridized) and carbon (sp hybridized); atoms which have p-acid character.
- Ligands A 2 can be monodentate, bidentate or tridentate, the denticity is defined by the number of donor atoms in the ligand.
- radiopharmaceuticals comprised of one or more ancillary or co-ligands A 2 are more stable compared to radiopharmaceuticals that are not comprised of one or more ancillary ligands, A L2 ; that is, they have a minimal number of isomeric forms, the relative ratios of which do not change significantly with time, and that remain substantially intact upon dilution.
- the ligands A 2 that are comprised of phosphine or arsine donor atoms are trisubstituted phosphines, trisubstituted arsines, tetrasubstituted diphosphines and tetrasubstituted diarsines.
- the ligands A 2 that are comprised of imine nitrogen are unsaturated or aromatic nitrogen-containing, 5 or 6-membered heterocycles.
- the ligands comprised of carbon (sp hybridized) donor atoms are isonitriles, comprised of the moiety CNR, where R is an organic radical.
- Isonitriles can be synthesized as described in European Patent 0107734 and in U.S. Patent 4,988,827, herein incorporated by reference.
- Preferred ancillary ligands A 2 are trisubstituted phosphines and unsaturated or aromatic 5 or 6 membered heterocycles.
- the most preferred ancillary ligands A L are trisubstituted phosphines and unsaturated 5 membered heterocycles .
- the ancillary ligands A L2 may be substituted with alkyl, aryl, alkoxy, heterocycle, aralkyl, alkaryl and arylalkaryl groups and may or may not bear functional groups comprised of heteroatoms such as oxygen, nitrogen, phosphorus or sulfur.
- functional groups include but are not limited to: hydroxyl, carboxyl, carboxamide, nitro, ether, ketone, amino, ammonium, sulfonate, sulfonamide, phosphonate, and phosphonamide.
- the functional groups may be chosen to alter the lipophilicity and water solubility of the ligands which may affect the biological properties of the radiopharmaceuticals, such as altering the distribution into non-target tissues, cells or fluids, and the mechanism and rate of elimination from the body.
- Chelators or bonding moieties for therapeutic radiopharmaceuticals are selected to form stable complexes with the radioisotopes that have alpha particle, beta particle, Auger or Coster-Kronig electron emissions, such as 186 Re, 188 Re, 153 Sm, 166 Ho, 177 Lu, 149 Pm , 90 ⁇ , 212 Bi/ 103 Pd , 109 Pd/ 159 Gd , 1 0 La/ 198 AU; 199 Au , " 9 Yb, 1 5 Yb, i e S Dy, 166 Dy, 6 Cu, iOS Rh, 1 :L Ag, and 1 2 Ir.
- Chelators for rhenium, copper, palladium, platinum, iridium, rhodium, silver and gold isotopes are selected from diaminedithiols, monoamine-monoamidedithiols, triamide-monothiols , monoamine-diamide-monothiols , diaminedioximes , and hydrazines.
- Chelators for yttrium, bismuth, and the lanthanide isotopes are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1, 4, 7 , 10- tetraazacyclododecane-l-acetic-4 ,7,10- tris (methylacetic) acid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl- 6-methyl-DTPA, and 6, 6 "-bis [N,N,N" ,N" - tetra(carboxymethyl) aminomethyl) -4 ' - (3-amino-4- methoxyphenyl ) -2 , 2 ' : 6 ' , 2 " -terpyridine .
- Chelators for magnetic resonance imaging contrast agents are selected to form stable complexes with paramagnetic metal ions, such as Gd(III), Dy(III), Fe(III), and Mn(II), are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1, 4, 7 , 10- tetraazacyclododecane-l-acetic-4, 7, 10- tris (methylacetic) acid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl- 6-methyl-DTPA, and 6, 6" -bis [N,N,N" ,N" - tetra (carboxymethyl) aminomethyl) -4 ' - (3-amino-4- methoxyphenyl) -2 , 2 ' : 6 ' , 2 " -terpyridine .
- the technetium and rhenium radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, an ancillary ligand A L , an ancillary ligand A L , and a reducing agent, in an aqueous solution at temperatures from 0 to 100 °C.
- the technetium and rhenium radiopharmaceuticals of the present invention comprised of a tetradentate chelator having two nitrogen and two sulfur atoms can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, and a reducing agent, in an aqueous solution at temperatures from 0 to 100 °C .
- the bonding unit in the reagent of the present invention When the bonding unit in the reagent of the present invention is present as a hydrazone group, then it must first be converted to a hydrazine, which may or may not be protonated, prior to complexation with the metal radionuclide.
- the conversion of the hydrazone group to the hydrazine can occur either prior to reaction with the radionuclide, in which case the radionuclide and the ancillary or co-ligand or ligands are combined not with the reagent but with a hydrolyzed form of the reagent bearing the chelator or bonding unit, or in the presence of the radionuclide in which case the reagent itself is combined with the radionuclide and the ancillary or co-ligand or ligands. In the latter case, the pH of the reaction mixture must be neutral or acidic.
- the radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be prepared by first admixing a salt of a radionuclide, an ancillary ligand LI, and a reducing agent in an aqueous solution at temperatures from 0 to 100 °C to form an intermediate radionuclide complex with the ancillary ligand A I then adding a reagent of the present invention and an ancillary ligand A 2 and reacting further at temperatures from 0 to 100°C.
- the radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be prepared by first admixing a salt of a radionuclide, an ancillary ligand A L I, a reagent of the present invention, and a reducing agent in an aqueous solution at temperatures from 0 to 100°C to form an intermediate radionuclide complex, and then adding an ancillary ligand A 2 and reacting further at temperatures from 0 to 100°C.
- the technetium and rhenium radionuclides are preferably in the chemical form of pertechnetate or perrhenate and a pharmaceutically acceptable cation.
- the pertechnetate salt form is preferably sodium pertechnetate such as obtained from commercial Tc-99m generators.
- the amount of pertechnetate used to prepare the radiopharmaceuticals of the present invention can range from 0.1 mCi to 1 Ci, or more preferably from 1 to 200 mCi.
- the amount of the reagent of the present invention used to prepare the technetium and rhenium radiopharmaceuticals of the present invention can range from 0.01 ⁇ g to 10 mg, or more preferably from 0.5 ⁇ g to 200 ⁇ g.
- the amount used will be dictated by the amounts of the other reactants and the identity of the radiopharmaceuticals of the present invention to be prepared.
- the amounts of the ancillary ligands A L ⁇ used can range from 0.1 mg to 1 g, or more preferably from 1 mg to 100 mg.
- the exact amount for a particular radiopharmaceutical is a function of identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the amounts and identities of the other reactants .
- Too large an amount of A L I will result in the formation of by-products comprised of technetium labeled A L ⁇ without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A L ⁇ but without the ancillary ligand L2 . Too small an amount of A L I will result in other by-products such as technetium labeled biologically active molecules with the ancillary ligand A L2 but without the ancillary ligand A L I, or reduced hydrolyzed technetium, or technetium colloid.
- the amounts of the ancillary ligands A L2 used can range from 0.001 mg to 1 g, or more preferably from 0.01 mg to 10 mg.
- the exact amount for a particular radiopharmaceutical is a function of the identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the amounts and identities of the other reactants.
- Too large an amount of A 2 will result in the formation of by-products comprised of technetium labeled A without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A L2 but without the ancillary ligand A L ⁇ - If the reagent bears one or more substituents that are comprised of a soft donor atom, as defined above, at least a ten-fold molar excess of the ancillary ligand A L to the reagent of formula 2 is required to prevent the substituent from interfering with the coordination of the ancillary ligand A L2 to the metal radionuclide.
- Suitable reducing agents for the synthesis of the radiopharmaceuticals of the present invention include stannous salts, dithionite or bisulfite salts, borohydride salts, and formamidinesulfinic acid, wherein the salts are of any pharmaceutically acceptable form.
- the preferred reducing agent is a stannous salt.
- the amount of a reducing agent used can range from 0.001 mg to 10 mg, or more preferably from 0.005 mg to 1 mg.
- Radiopharmaceuticals comprised of a hydrazido or diazenido bonding unit will depend on the identity of the reagent of the present invention used, the identity of any ancillary ligand ALI, the identity of any ancillary ligand AL 2 , and the identity of the radionuclide.
- Radiopharmaceuticals comprised of a hydrazido or diazenido bonding unit synthesized using concentrations of reagents of ⁇ 100 ⁇ g/mL, will be comprised of one hydrazido or diazenido group.
- Those synthesized using >1 mg/mL concentrations will be comprised of two hydrazido or diazenido groups from two reagent molecules.
- the biologically active molecule can be injected and not result in undesired side-effects, such as chemical toxicity, interference with a biological process or an altered biodistribution of the radiopharmaceutical. Therefore, the radiopharmaceuticals which require higher concentrations of the reagents comprised in part of the biologically active molecule, will have to be diluted or purified after synthesis to avoid such side-effects.
- the identities and amounts used of the ancillary ligands ALI and A 2 will determine the values of the variables y and z .
- the values of y and z can independently be an integer from 1 to 2. In combination, the values of y and z will result in a technetium coordination sphere that is made up of at least five and no more than seven donor atoms .
- Z can be an integer from 1 to 2;
- bidentate or tridentate ancillary ligands A 2 z is 1.
- the preferred combination for monodentate ligands is y equal to 1 or 2 and z equal to 1.
- the preferred combination for bidentate or tridentate ligands is y equal to 1 and z equal to 1.
- the indium, copper, gallium, silver, palladium, rhodium, gold, platinum, bismuth, yttrium and lanthanide radiopharmaceuticals of the present invention can be easily prepared by admixing a salt of a radionuclide and a reagent of the present invention, in an aqueous solution at temperatures from 0 to 100°C.
- These radionuclides are typically obtained as a dilute aqueous solution in a mineral acid, such as hydrochloric, nitric or sulfuric acid.
- the radionuclides are combined with from one to about one thousand equivalents of the reagents of the present invention dissolved in aqueous solution.
- a buffer is typically used to maintain the pH of the reaction mixture between 3 and 10.
- the gadolinium, dysprosium, iron and manganese metallopharmaceuticals of the present invention can be easily prepared by admixing a salt of the paramagnetic metal ion and a reagent of the present invention, in an aqueous solution at temperatures from 0 to 100 °C.
- These paramagnetic metal ions are typically obtained as a dilute aqueous solution in a mineral acid, such as hydrochloric, nitric or sulfuric acid.
- the paramagnetic metal ions are combined with from one to about one thousand equivalents of the reagents of the present invention dissolved in aqueous solution.
- a buffer is typically used to maintain the pH of the reaction mixture between 3 and 10.
- the total time of preparation will vary depending on the identity of the metal ion, the identities and amounts of the reactants and the procedure used for the preparation.
- the preparations may be complete, resulting in > 80% yield of the radiopharmaceutical, in 1 minute or may require more time. If higher purity metallopharmaceuticals are needed or desired, the products can be purified by any of a number of techniques well known to those skilled in the art such as liquid chromatography, solid phase extraction, solvent extraction, dialysis or ultrafiltration.
- Buffers useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, and acetate. A more complete list can be found in the United States Pharmacopeia.
- Lyophilization aids useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidine (PVP) .
- Stabilization aids useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol.
- Solubilization aids useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monoloeate, polysorbates, poly (oxyethylene) poly (oxypropylene) poly (oxyethylene) block copolymers (Pluronics) and lecithin.
- Preferred solubilizing aids are polyethylene glycol, and Pluronics .
- Bacteriostats useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol, and methyl, propyl or butyl paraben.
- a component in a diagnostic kit can also serve more than one function.
- a reducing agent can also serve as a stabilization aid
- a buffer can also serve as a transfer ligand
- a lyophilization aid can also serve as a transfer, ancillary or co-ligand and so forth.
- the diagnostic radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 1 to 100 mCi per 70 kg body weight, or preferably at a dose of 5 to 50 mCi . Imaging is performed using known procedures.
- the therapeutic radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 0.1 to 100 mCi per 70 kg body weight, or preferably at a dose of 0.5 to 5 mCi per 70 kg body weight.
- the magnetic resonance imaging contrast agents of the present invention may be used in a similar manner as other MRI agents as described in U.S. Patent 5,155,215; U.S. Patent 5,087,440; Margerstadt et al . , Magn. Reson. Med., 1986, 3, 808; Runge et al . , Radiology, 1988, 166, 835; and Bousquet et al . , Radiology, 1988, 166, 693.
- sterile aqueous solutions of the contrast agents are administered to a patient intravenously in dosages ranging from 0.01 to 1.0 mmoles per kg body weight .
- the compositions of the present invention should generally have a heavy atom concentration of 1 mM to 5 M, preferably 0.1 M to 2 M.
- Dosages, administered by intravenous injection will typically range from 0.5 mmol/kg to 1.5 mmol/kg, preferably 0.8 mmol/kg to 1.2 mmol/kg.
- Imaging is performed using known techniques, preferably X-ray computed tomography.
- the ultrasound contrast agents of the present invention are administered by intravenous injection in an amount of 10 to 30 ⁇ L of the echogenic gas per kg body weight or by infusion at a rate of approximately 3 ⁇ L/kg/min. Imaging is performed using known techniques of sonography.
- Boc-L-cysteic acid, Boc-L- cysteic acid N-hydroxyphenyl ester, and Boc-L-cysteic acid p-nitrophenyl ester were prepared as described in Liebigs Ann. Chem. 1979, 776-783.
- 2- (lH-Benzotriazol-1- yl ) -1 , 1 , 3 , 3-tetramethyluronium hexafluorophosphate (HBTU) and TBTU were purchased from Advanced ChemTech.
- N-methylmorpholine (NMM) m-cresol, D-2-aminobutyric acid (Abu) , trimethylacetylchloride, diisopropylethylamine (DIEA) , 1 , 2 , 4-triazole, stannous chloride dihydrate, 1- (3-dimethylaminopropyl) -3- doctrineethylcarbodiimide hydrochloride (EDC) , triethylsilane (Et 3 SiH) , and tris (3-sulfonatophenyl)phosphine trisodium salt (TPPTS) were purchased from Aldrich Chemical
- TPDS Bis (3-sulfonatophenyl)phenylphosphine disodium salt
- TPPMS (3- Sulfonatophenyl) diphenylphosphine monosodium salt
- Tricine was obtained from Research Organics, Inc.
- Technetium-99m- pertechnetate 99 Tc ⁇ 4 ⁇
- In-111- chloride In-111- chloride (Indichlor®) was obtained from Amersham Medi- Physics, Inc.
- Biphenyl-4, 4 ' -disulfonyl chloride (2.64 g, 7.5 mmol, freshly recrystallized from CHCI 3 ) and DCM (200 mL) were placed in a 500 mL 3-neck flask fitted with a thermometer, an addition funnel, and a nitrogen line.
- the addition funnel was charged with a solution of N-(3- (2- (2- (3-aminopropoxy) ethoxy) ethoxy) propyl) - (phenylmethoxy) formamide (1.77 g, 5.0 mmol) and DIEA (0.87 mL, 5.0 mmol) in DCM (40 mL) .
- the contents of the flask were cooled below 5 °C.
- the contents of the addition funnel were added to the flask with rapid stirring over 3 h while keeping the temperature of the flask below 5 °C.
- the addition funnel was charged with a solution of N- ⁇ -Boc-L- ⁇ , ⁇ , -diaminopropionic acid methyl ester hydrochloride (2.55 g, 10 mmol) and DIEA (3.8 mL, 22 mmol) in DCM (25 mL) .
- This solution was added to the flask with stirring at 5 °C over 15 min, and stirred at ambient temperatures for an additional 20 h.
- the reaction solution was washed consecutively with 0.1 N HCI (100 mL) and water (2 x 100 mL) , dried (MgS ⁇ ) , and concentrated to give a viscous oil (5.79 g) .
- the dimeric product from Part A, above (11 mg. 0.0050 mmol) was dissolved in degassed TFA (2 mL) and stirred at ambient temperatures under a nitrogen atmosphere for 15 min and concentrated to a viscous amber oil. This oil was dissolved in anhydrous DMF (2 mL) and made basic with TEA. The solution was treated with 2- (2-aza-2- ( (5- ( (2 , 5-dioxopyrrolidinyl) carbonyl) (2- pyridyl) ) amino) vinyl) benzenesulfonic acid (0.024 mmol) and stirred at ambient temperatures under a nitrogen atmosphere for 56 h.
- Part B 2-(l, 4, 7, lO-tetraaza-4, 7, 10-tris ( ( (tert- butyl) oxycarbonyl)methyl) cyclododecyl) acetic acid
- the resulting amber oil was dissolved in 10% ACN and purified by preparative HPLC on a Vydac C-18 column (22 x 250 mm) using a 2.1%/min gradient pof 0 to 63% ACN containing 0.1% TFA at a flow rate of 20 mL/min.
- the main product peak eluting at 23.0 min was collected and lyophilized to give the title compound as a colorless, hygroscopic solid (22 mg, 37%).
- Methyl 2- ( (phenyImethoxy) -carbonylamino-3- ( (1- (3- ( (1- (triphenylmethyl) imidazol-2-yl) amino) propyl ) (lH-indazol- 5-yl)) carbonylamino)propanoate (1.55 g, 2.03 mmol) was dissolved in tetrahydrofuran (20 mL) .
- Lithium hydroxide monohydrate (1.71 g, 40.6 mmol) was dissolved in water and added to the reaction. The reaction was stirred overnight under N2 for 18h. The tetrahydrofuran was removed under high vacuum. The pH of the remaining aqueous layer was adjusted to 5 with IN HCI.
- Triethylamine (20.1 ⁇ L, 0.144 mmol) is added, and after 5 min of stirring 2- [ [ [5- [ [ (2 , 5-dioxo-l- pyrrolidinyl) oxy] carbonyl] -2-pyridinyl] ydrazono] - methyl] -benzenesulfonic acid, monosodium salt (0.0254 g, 0.0577 mmol) is added. The reaction mixture is stirred for 20 h and then concentrated to an oil under high vacuum. The oil is purified by preparative RP-HPLC to obtain the desired product.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU7002501A AU7002501A (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
AU2001270025A AU2001270025B2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
EP01948554A EP1296678A2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
CA002413957A CA2413957A1 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21321200P | 2000-06-21 | 2000-06-21 | |
US60/213,212 | 2000-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001098294A2 true WO2001098294A2 (en) | 2001-12-27 |
WO2001098294A3 WO2001098294A3 (en) | 2003-01-09 |
Family
ID=22794180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/019794 WO2001098294A2 (en) | 2000-06-21 | 2001-06-21 | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1296678A2 (en) |
AU (2) | AU2001270025B2 (en) |
CA (1) | CA2413957A1 (en) |
WO (1) | WO2001098294A2 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001091805A2 (en) * | 2000-06-02 | 2001-12-06 | Bracco Research Usa | Compounds for targeting endothelial cells |
WO2001097848A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
WO2001097861A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6683163B2 (en) | 1998-12-18 | 2004-01-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1420792A2 (en) * | 2001-08-01 | 2004-05-26 | SmithKline Beecham Corporation | Products and drug delivery vehicles |
WO2005009963A1 (en) * | 2003-06-13 | 2005-02-03 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals tihereof |
US7018611B2 (en) | 1998-12-18 | 2006-03-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1724259A1 (en) * | 2004-03-19 | 2006-11-22 | Speedel Experimenta AG | 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
EP1800676A1 (en) * | 2005-12-23 | 2007-06-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Cancer chemotherapy |
CN100369606C (en) * | 2004-04-15 | 2008-02-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and preparation |
CN100471496C (en) * | 2004-04-15 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and its powder injection |
WO2010092114A1 (en) | 2009-02-13 | 2010-08-19 | Guerbet | Use of buffers for radionuclide complexation |
US7968536B2 (en) | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
WO2012084981A1 (en) | 2010-12-20 | 2012-06-28 | Guerbet | Chelate nanoemulsion for mri |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US8293752B2 (en) | 2007-06-29 | 2012-10-23 | Millennium Pharmaceuticals, Inc. | Compounds useful as Raf kinase inhibitors |
WO2013045333A1 (en) | 2011-09-26 | 2013-04-04 | Guerbet | Nanoemulsions and use thereof as contrast agents |
WO2014114724A1 (en) | 2013-01-23 | 2014-07-31 | Guerbet | Vectorised magnetic emulsion |
US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
WO2015046278A1 (en) * | 2013-09-24 | 2015-04-02 | 富士フイルム株式会社 | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
US9421175B2 (en) | 2004-03-17 | 2016-08-23 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
CN107428755A (en) * | 2015-03-25 | 2017-12-01 | 富士胶片株式会社 | The manufacture method and their manufacture intermediate of new nitrogen-containing compound or its salt |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
US11103483B2 (en) | 2010-01-28 | 2021-08-31 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113368235B (en) * | 2021-05-11 | 2022-11-15 | 上海师范大学 | Gd-NGQDs/BTS @ PLGA-PEG nano material and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0095906A1 (en) * | 1982-05-27 | 1983-12-07 | National Research Development Corporation | Improvements relating to compounds useful in radiotherapy or chemotherapy |
WO1997023480A1 (en) * | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
EP0819430A1 (en) * | 1996-07-17 | 1998-01-21 | Takeda Chemical Industries, Ltd. | Inhibitor of tumor metastasis or recurrence |
WO1998047541A1 (en) * | 1997-04-24 | 1998-10-29 | Nycomed Imaging As | Contrast agents |
WO1999006347A1 (en) * | 1997-07-31 | 1999-02-11 | Yeda Research And Development Company Ltd. | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives |
WO1999040947A2 (en) * | 1998-02-11 | 1999-08-19 | Resolution Pharmaceuticals Inc. | Angiogenesis targeting molecules |
WO1999058162A2 (en) * | 1998-03-31 | 1999-11-18 | Du Pont Pharmaceuticals Company | Pharmaceuticals for the imaging of angiogenic disorders |
WO2000018439A2 (en) * | 1998-09-29 | 2000-04-06 | Schering Aktiengesellschaft | Use of neoangiogenesis markers for diagnosing and treating tumours by therapy |
WO2000035488A2 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
-
2001
- 2001-06-21 CA CA002413957A patent/CA2413957A1/en not_active Abandoned
- 2001-06-21 EP EP01948554A patent/EP1296678A2/en not_active Withdrawn
- 2001-06-21 WO PCT/US2001/019794 patent/WO2001098294A2/en active IP Right Grant
- 2001-06-21 AU AU2001270025A patent/AU2001270025B2/en not_active Ceased
- 2001-06-21 AU AU7002501A patent/AU7002501A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0095906A1 (en) * | 1982-05-27 | 1983-12-07 | National Research Development Corporation | Improvements relating to compounds useful in radiotherapy or chemotherapy |
WO1997023480A1 (en) * | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
EP0819430A1 (en) * | 1996-07-17 | 1998-01-21 | Takeda Chemical Industries, Ltd. | Inhibitor of tumor metastasis or recurrence |
WO1998047541A1 (en) * | 1997-04-24 | 1998-10-29 | Nycomed Imaging As | Contrast agents |
WO1999006347A1 (en) * | 1997-07-31 | 1999-02-11 | Yeda Research And Development Company Ltd. | The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives |
WO1999040947A2 (en) * | 1998-02-11 | 1999-08-19 | Resolution Pharmaceuticals Inc. | Angiogenesis targeting molecules |
WO1999058162A2 (en) * | 1998-03-31 | 1999-11-18 | Du Pont Pharmaceuticals Company | Pharmaceuticals for the imaging of angiogenic disorders |
WO2000018439A2 (en) * | 1998-09-29 | 2000-04-06 | Schering Aktiengesellschaft | Use of neoangiogenesis markers for diagnosing and treating tumours by therapy |
WO2000035488A2 (en) * | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
Non-Patent Citations (1)
Title |
---|
D.G. BATT ET AL: J. MED. CHEM., vol. 43, no. 1, 2000, pages 41-58, XP000915237 * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569402B1 (en) | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US7090828B2 (en) | 1998-12-18 | 2006-08-15 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US7018611B2 (en) | 1998-12-18 | 2006-03-28 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6743412B2 (en) | 1998-12-18 | 2004-06-01 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6689337B2 (en) | 1998-12-18 | 2004-02-10 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6683163B2 (en) | 1998-12-18 | 2004-01-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP2279757A3 (en) * | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
US7109167B2 (en) | 2000-06-02 | 2006-09-19 | Bracco International B.V. | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
EP2286843A3 (en) * | 2000-06-02 | 2011-08-03 | Bracco Suisse SA | Compounds for targeting endothelial cells |
WO2001091805A3 (en) * | 2000-06-02 | 2002-09-06 | Bracco Res Usa | Compounds for targeting endothelial cells |
WO2001091805A2 (en) * | 2000-06-02 | 2001-12-06 | Bracco Research Usa | Compounds for targeting endothelial cells |
US7884183B2 (en) | 2000-06-02 | 2011-02-08 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US7820621B2 (en) | 2000-06-02 | 2010-10-26 | Bracco International B.V. | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
WO2001097861A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
WO2001097848A3 (en) * | 2000-06-21 | 2003-03-13 | Bristol Myers Squibb Pharma Co | Vitronectin receptor antagonist pharmaceuticals |
WO2001097861A3 (en) * | 2000-06-21 | 2003-02-27 | Bristol Myers Squibb Pharma Co | Vitronectin receptor antagonist pharmaceuticals |
WO2001097848A2 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
EP1420792A4 (en) * | 2001-08-01 | 2007-10-10 | Smithkline Beecham Corp | Products and drug delivery vehicles |
EP1420792A2 (en) * | 2001-08-01 | 2004-05-26 | SmithKline Beecham Corporation | Products and drug delivery vehicles |
US7319149B2 (en) | 2003-06-13 | 2008-01-15 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals thereof |
WO2005009963A1 (en) * | 2003-06-13 | 2005-02-03 | Bristol-Myers Squibb Pharma Company | Chelants and macrocyclic metal complex radiopharmaceuticals tihereof |
US9421175B2 (en) | 2004-03-17 | 2016-08-23 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
EP1724259A1 (en) * | 2004-03-19 | 2006-11-22 | Speedel Experimenta AG | 2,7-substituted 5-amino-4-hydroxy-8-(1h-indazol-5-yl)-octan amide derivatives and related compounds as renin inhibitors for the treatment of hypertension |
CN100471496C (en) * | 2004-04-15 | 2009-03-25 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and its powder injection |
CN100369606C (en) * | 2004-04-15 | 2008-02-20 | 中国人民解放军军事医学科学院毒物药物研究所 | Inclusion containing raltitrexed and preparation |
US8926945B2 (en) | 2005-10-07 | 2015-01-06 | Guerbet | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
EP1800676A1 (en) * | 2005-12-23 | 2007-06-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Cancer chemotherapy |
US9556177B2 (en) | 2007-06-29 | 2017-01-31 | Millennium Pharmaceuticals, Inc. | Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors |
US9920048B2 (en) | 2007-06-29 | 2018-03-20 | Millennium Pharmaceuticals, Inc. | Substituted pyrimidines for inhibiting Raf kinase activity |
US8802657B2 (en) | 2007-06-29 | 2014-08-12 | Millennium Pharmaceuticals, Inc. | Compounds useful as Raf kinase inhibitors |
US8293752B2 (en) | 2007-06-29 | 2012-10-23 | Millennium Pharmaceuticals, Inc. | Compounds useful as Raf kinase inhibitors |
US7968536B2 (en) | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
WO2010092114A1 (en) | 2009-02-13 | 2010-08-19 | Guerbet | Use of buffers for radionuclide complexation |
US11872214B2 (en) | 2010-01-28 | 2024-01-16 | Eagle Pharmaceuticals, Inc. | Formulations of Bendamustine |
US11103483B2 (en) | 2010-01-28 | 2021-08-31 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
WO2012084981A1 (en) | 2010-12-20 | 2012-06-28 | Guerbet | Chelate nanoemulsion for mri |
US9770520B2 (en) | 2010-12-20 | 2017-09-26 | Guerbet | Chelate nanoemulsion for MRI |
WO2013045333A1 (en) | 2011-09-26 | 2013-04-04 | Guerbet | Nanoemulsions and use thereof as contrast agents |
WO2014114724A1 (en) | 2013-01-23 | 2014-07-31 | Guerbet | Vectorised magnetic emulsion |
WO2015046278A1 (en) * | 2013-09-24 | 2015-04-02 | 富士フイルム株式会社 | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
JP2018027961A (en) * | 2013-09-24 | 2018-02-22 | 富士フイルム株式会社 | Complex of new nitrogen-containing compound or its salt or complex of the same and metal |
EP3929196A1 (en) * | 2013-09-24 | 2021-12-29 | FUJIFILM Corporation | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
US11426473B2 (en) | 2013-09-24 | 2022-08-30 | Fujifilm Corporation | Nitrogen-containing compound or salt thereof, or metal complex thereof |
EP4249471A3 (en) * | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
JPWO2015046278A1 (en) * | 2013-09-24 | 2017-03-09 | 富士フイルム株式会社 | Novel nitrogen-containing compounds or salts thereof or complexes thereof with metals |
CN107428755B (en) * | 2015-03-25 | 2020-03-03 | 富士胶片株式会社 | Process for producing nitrogen-containing compound or salt thereof, and intermediate for production thereof |
CN107428755A (en) * | 2015-03-25 | 2017-12-01 | 富士胶片株式会社 | The manufacture method and their manufacture intermediate of new nitrogen-containing compound or its salt |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2001098294A3 (en) | 2003-01-09 |
EP1296678A2 (en) | 2003-04-02 |
AU2001270025B2 (en) | 2005-08-18 |
CA2413957A1 (en) | 2001-12-27 |
AU7002501A (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6322770B1 (en) | Indazole vitronectin receptor antagonist pharmaceuticals | |
US6743412B2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
EP1296678A2 (en) | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | |
AU2001270025A1 (en) | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy | |
US6524553B2 (en) | Quinolone vitronectin receptor antagonist pharmaceuticals | |
US6838074B2 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
EP1311292A2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
EP1140203B1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
US6511649B1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
US7090828B2 (en) | Vitronectin receptor antagonist pharmaceuticals | |
AU2002331042A1 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
EP1423152A2 (en) | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | |
EP1307226B1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
AU2001272965A1 (en) | Vitronectin receptor antagonist pharmaceuticals | |
US6794518B1 (en) | Vitronectin receptor antagonist pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2413957 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001270025 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001948554 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001948554 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001948554 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001270025 Country of ref document: AU |